

KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY,  
KUMASI.

COLLEGE OF HEALTH SCIENCES  
SCHOOL OF MEDICAL SCIENCES  
DEPARTMENT OF CLINICAL MICROBIOLOGY



**PREVALENCE OF SALMONELLA AND OTHER GRAM NEGATIVE  
BACTERIAL INFECTIONS AMONG FEVER AND DIARRHOEAL  
PATIENTS VISITING HALF-ASSINI GOVERNMENT HOSPITAL**

A THESIS SUBMITTED TO THE DEPARTMENT OF CLINICAL  
MICROBIOLOGY,  
IN FULFILLMENT OF THE REQUIREMENT FOR THE AWARD OF THE  
DEGREE OF  
**MASTER OF PHILOSOPHY IN CLINICAL MICROBIOLOGY**

**BY**

**JOHN GAMELI DEKU**

**JUNE, 2016**

## DECLARATION

### Candidate's declaration

I affirm with certainty that this project work was carried out by me at Half-Assini Government Hospital, and it is the result of my own original research towards the award of Master of Philosophy in Clinical Microbiology, and that to the best of my knowledge, it contains no material previously published by another person or material which has been accepted for award of any other degree of the University, except where due acknowledgement has been made in the text.

Candidate's name: John Gameli Deku .....

Signature

Date

Dr. Patrick Kwame Feglo .....

(Supervisor)

Signature


Date

Dr. Theophilus Benjamin Kwofie .....

(Head of Department)

Signature


Date



# KNUST

## DEDICATION

This thesis is dedicated in honour of my wife Philipine Esiawonam Deku. It is also to my children; Nelly Selikplim Deku and Kenny Seyram Deku.



# GNUST

## ACKNOWLEDGEMENT

“For His grace is sufficient for me.” I show my first appreciation to God. He who endowed me with all that I need and by His grace and mercy, I was able to come out with this work.

I was fortunate in having Dr. Patrick Kwame Feglo, a very experienced lecturer as my supervisor. I express my sincere gratitude to him for the time he spent on this work and for his helpful suggestions and guidance, for me to be able to come out with this work. To the Medical Superintendent at Half-Assini government Hospital, I cannot thank you enough. I salute all the lecturers and staff of Department of Clinical Microbiology, Kwame Nkrumah University of Science and Technology, Kumasi for their guidance and direction.

I am equally grateful to Dr. Kalpy Julien Coulibaly and staff of Institut Pasteur de Côte d'Ivoire. Indeed, your hearts are made of gold. I am also grateful to all friends and coworkers who helped in diverse ways and contributed to the completion of this thesis.

## TABLE OF CONTENTS

|   |          |
|---|----------|
| DECLARATION .....   | II       |
| DEDICATION .....  | III      |
| ACKNOWLEDGEMENT .....   | IV       |
| TABLE OF CONTENTS .....   | V        |
| APPENDICES .....  | IX       |
| LIST OF TABLES .....  | XI       |
| LIST OF FIGURES .....   | XII      |
| ABBREVIATIONS .....   | XIII     |
| ABSTRACT.....   | IV       |
| CHAPTER ONE .....   | <u>1</u> |
| 1.0 INTRODUCTION .....  | 1        |
| 1.1 PROBLEM STATEMENT .....   | 2        |
| 1.2 JUSTIFICATION OF THE STUDY .....  | 3        |
| 1.3 AIM OF THIS STUDY.....  | 3        |
| 1.4 OBJECTIVE OF THIS STUDY .....   | 4        |
| CHAPTER TWO: LITERATURE REVIEW .....  | 5        |
| 2.1 THE SALMONELLA ORGANISM.....  | 5        |
| 2.2 CLASSIFICATION OF SALMONELLA AND OTHER GRAM NEGATIVE<br>BACTERIA .....                                  | 6        |
| 2.3 EPIDEMIOLOGY AND BURDEN OF THE SALMONELLA AND OTHER GRAM<br>NEGATIVE BACTERIAL INFECTION .....          | 8        |
| 2.4 AGE DISTRIBUTION AND BURDEN OF INFECTION CAUSED BY<br>SALMONELLA AND OTHER GRAM NEGATIVE BACTERIA ..... | 9        |
| 2.5 PATHOGENESIS OF SALMONELLA .....  | 10       |

|   |        |
|---|--------|
| 2.6 CLINICAL PRESENTATION OF SALMONELLA AND OTHER GRAM<br>NEGATIVE BACTERIA .....                               | 11     |
| 2.7 ANTIMICROBIAL SUSCEPTIBILITY OF SALMONELLA AND OTHER GRAM<br>NEGATIVE BACTERIA.....                         | 12 2.8 |
| EPIDEMIOLOGY OF BACTERIA EXPRESSING EXTENDED SPECTRUM<br>BETA LACTAMASE .....                                   | 14     |
| 2.9 TRANSMISSION OF SALMONELLA AND OTHER GRAM NEGATIVE<br>BACTERIA.....   | 15     |
| 2.10 RISK FACTORS FOR TRANSMISSION SALMONELLA AND OTHER GRAM<br>NEGATIVE BACTERIA.....                          | 16     |
| 2.10.1 ENVIRONMENTAL RISK FACTORS FOR TRANSMISSION OF<br>SALMONELLA.. .....                                     | 16     |
| 2.10.1.1 FOOD AND WATER AS A RISK FACTOR FOR TRANSMISSION OF<br>SALMONELLA. ....                                | 16     |
| 2.10.1.2 ZOONOSIS AS A RISK FACTOR FOR TRANSMISSION OF SALMONELLA<br>AND GRAM NEGATIVE BACTERIA .....           | 17     |
| 2.10.1.3 NOSOCOMIAL RISK FACTORS FOR TRANSMISSION OF SALMONELLA<br>AND OTHER GRAM NEGATIVE BACTERIA .....       | 17     |
| 2.10.2 HOST RISK FACTORS FOR TRANSMISSION OF SALMONELLA AND<br>OTHER GRAM NEGATIVE BACTERIA .....               | 17     |
| 2.10.2.1 AGE AS A RISK FACTOR FOR TRANSMISSION OF SALMONELLA AND<br>OTHER GRAM NEGATIVE BACTERIA .....          | 17     |
| 2.10.2.2 EXPOSURE TO ANTIMICROBIAL AGENTS AS A RISK FACTOR FOR<br>TRANSMISSION OF SALMONELLA .....              | 18     |
| 2.10.2.3 ACHLORHYDRIA AS A RISK FACTOR FOR TRANSMISSION OF<br>SALMONELLA AND OTHER GRAM NEGATIVE BACTERIA ..... | 18     |
| 2.10.2.4 MALARIA INFESTATION AS A RISK FACTOR FOR TRANSMISSION OF<br>SALMONELLA .....                           | 18     |
| 2.10.2.5 MALNUTRITION AS A RISK FACTOR FOR TRANSMISSION OF<br>SALMONELLA AND OTHER GRAM NEGATIVE BACTERIA ..... | 19     |
| 2.10.2.6 HIV INFECTION AS A RISK FACTOR FOR TRANSMISSION OF<br>SALMONELLA .....                                 | 19     |
| 2.11.0 PREVENTION OF INFECTION CAUSED BY SALMONELLA AND OTHER<br>GRAM NEGATIVE BACTERIA .....                   | 19     |
| 2.12 OTHER GRAM NEGATIVE PATHOGENS.....   | 20     |
| CHAPTER THREE MATERIALS AND METHODS .....   | 23     |
| 3.1 THE STUDY AREA .....  | 23     |
| 3.2 ETHICAL APPROVAL .....  | 23     |
| 3.3 THE STUDY PATIENTS .....  | 23     |
| 3.3.1 INCLUSION CRITERIA OF THE STUDY PATIENTS .....  | 23     |



|   |           |
|---|-----------|
| 4.3 PREVALENCE OF SALMONELLA AND OTHER GRAM NEGATIVE BACTERIA .....                               | 37        |
| 4.4 BACTERIAL ISOLATES AND GENDER OF THE STUDY PATIENTS .....                                     | 37        |
| 4.5 BACTERIAL ISOLATES AND COUNTRY OF ORIGIN OF THE STUDY PATIENTS .....                          | 38        |
| 4.6 BACTERIAL ISOLATES AND RELIGION OF THE STUDY PATIENTS .....                                   | 38        |
| 4.7 BACTERIAL ISOLATES AND EDUCATIONAL STATUS OF THE STUDY PATIENTS .....                         | 38        |
| 4.8 ANTIMICROBIAL SUSCEPTIBILITY AND ESBL TEST RESULTS .....                                      | 39        |
| 4.9 CHARACTERISATION OF SALMONELLA ISOLATES BY PULSED –FIELD GEL ELECTROPHORESIS .....            | 41        |
| CHAPTER FIVE DISCUSSION .....   | 42        |
| 5.1 THE BACTERIAL ISOLATES OBTAINED IN RELATION TO THE AGE OF PATIENTS .....                      | 42        |
| 5.2 THE BACTERIAL ISOLATES OBTAINED IN RELATION TO THE GENDER OF THE PATIENTS .....               | 43        |
| 5.3 THE BACTERIAL ISOLATES OBTAINED IN RELATION TO THE SAMPLE FROM WHICH THEY WERE ISOLATED ..... | 44        |
| 5.4 ANTIMICROBIAL SUSCEPTIBILITY OF THE BACTERIAL ISOLATES .....                                  | 44        |
| 5.5 THE BACTERIAL ISOLATES AND EXTENDED SPECTRUM BETA LACTAMASE PRODUCTION .....                  | 45        |
| CHAPTER SIX CONCLUSION AND RECOMMENDATION.....  | 47        |
| 6.1 CONCLUSION .....  | 47        |
| 6.2 RECOMMENDATIONS .....   | 48        |
| REFERENCES .....  | 49        |
| <b>APPENDICES.....</b>  | <b>56</b> |
| APPENDIX 3.7.1A COMPOSITION AND PREPARATION OF CULTURE MEDIA..                                    | 56        |
| APPENDIX 3.7.1B DISPENSING OF THE PREPARED MEDIA.....   | 64        |
| APPENDIX3.10 IDENTIFICATION OF THE ISOLATES USING ANALYTICAL PROFILE INDEX.....                   | 64        |
| APPENDIX 3.12.1 PRINCIPLE OF UREASE TEST.....   | 66        |

|  |                             |    |
|--|-----------------------------|----|
| APPENDIX 3.12.2 PRINCIPLE OF THE   | MOTILITY, INDOLE, ORNITHINE |    |
| TEST.....  |                             | 66 |
| APPENDIX 3.12.3 PRINCIPLE OF THE TRIPLE SUGAR IRON AGAR TEST.....                          |                             | 67 |
| APPENDIX 3.12.4 PRINCIPLE OF THE CITRATE TEST.....   |                             | 67 |
| APPENDIX 3.13.0 PRINCIPLE OF THE SEROLOGICAL TEST.....                                     |                             | 67 |
| APPENDIX 3.14 PREPARATION OF 0.5 MCFARLAND.....  |                             | 64 |
| APPENDIX 3.15 PRINCIPLE OF EXTENDED SPECTRUM BETA LACTAMASE<br>DETECTION.....              |                             | 68 |
| APPENDIX 3.16 PRINCIPLE BEHIND PULSED-FIELD<br>ELECTROPHORESIS.....                        |                             | 68 |
| APPENDIX 3.16.1 PROCEDURE FOR PULSED FIELD<br>ELECTROPHORESIS.....                         |                             | 68 |
| APPENDIX 3.16.1 CONSTITUENTS OF REAGENTS USED FOR PULSED-FIELD<br>GEL ELECTROPHORESIS..... |                             | 72 |
| APPENDIX 3.16.1 R1: CELL SUSPENSION BUFFER (100MM TRIS: 100MM EDTA,<br>PH 8).....          |                             | 72 |
| APPENDIX 3.16.1 R2: PROTEINASE-K (20MG/ML).....  |                             | 72 |
| APPENDIX 3.16.1 R3: 1% SEAKEM GOLD AGAROSE:1% SDS MIXTURE.....                             |                             | 72 |
| APPENDIX 3.16.1 R4: LYSIS BUFFER.....  |                             | 72 |
| APPENDIX 3.16.1 R5: TRIS-EDTA (TE) BUFFER (10MM TRIS: 1MM EDTA,<br>PH 8).....              |                             | 72 |
| APPENDIX 3.16.1 R6: 1X RESTRICTION ENZYME BUFFER.....                                      |                             | 72 |
| APPENDIX 3.16.1 R7: 1X RESTRICTION ENZYME BUFFER WITH RESTRICTION                          |                             |    |

|  |      |
|--|------|
| ENZYME.....  | 72   |
| APPENDIX 3.16.1 R8: 0.5X TBE BUFFER.....                     | 73   |
| APPENDIX 3.16.1 R9: 1% SEAKEM GOLD AGAROSE.....              | 73   |
| APPENDIX 3.16.1 R10: ETHIDIUM BROMIDE STAINING SOLUTION..... | 7369 |
| APPENDIX 3.16.1 R11: 10% SDS.....                            | 73   |
| APPENDIX 3.16.1 R12: 10X TBE BUFFER.....                     | 73   |

**LIST OF TABLES**

|   |    |
|---|----|
| TABLE 4.1 DEMOGRAPHIC CHARACTERISTICS OF THE STUDY PATIENTS STRATIFIED BY BACTERIAL ISOLATES..... | 35 |
| TABLE 4.2 PROPORTIONS OF POSITIVE BACTERIA ISOLATED.....  | 36 |
| TABLE 4.3 BACTERIAL ISOLATES AND SAMPLES FROM WHICH THEY WERE ISOLATED.....                       | 37 |
| TABLE 4.4 ANTIMICROBIAL SUSCEPTIBILITY TEST RESULTS OF THE ISOLATES OBTAINED AT HALF- ASSINI..... | 40 |

## LIST OF FIGURES

FIGURE 2.1 THE SALMONELLA ORGANISM.....5


FIGURE 4.1 PFGE IMAGES OF SALMONELLA CHOLERAESUIS AND SALMONELLA TYPHI.....41

## LIST OF ABBREVIATIONS

|                 |  |
|-----------------|--|
| µg              | Microgram                                  |
| CD4             | Cluster of differentiation                 |
| CDC             | Centres for Disease Control and Prevention |
| DNA             | Deoxyribonucleic acid                      |
| EDTA            | Ethylenediamine tetraacetic acid           |
| g               | Gram                                       |
| L               | Litre                                      |
| ml              | Millilitres                                |
| mm <sup>3</sup> | Cubic millimetre                           |
| °C              | Degree Celsius                             |
| PFGE            | Pulsed-Field Gel Electrophoresis           |
| rpm             | Revolution per minute                      |
| SDS             | Sodium dodecyl sulphate                    |
| TBE             | Tris Borate EDTA                           |

## ABSTRACT

Infections with *Salmonella* and other Gram negative bacteria are becoming more difficult to treat due to their resistance to commonly available antibiotics. Also, some district laboratories are not fully equipped to perform diagnostic tests to isolate and identify these pathogens. There have been reports of antimicrobial resistance as a result of production of Extended Spectrum Beta Lactamase (ESBL) in Accra and Kumasi but no such study has been done in Half-Assini. This study was therefore undertaken to determine the prevalence of *Salmonella* and other Gram negative organisms, their antimicrobial susceptibility pattern together with whether they were ESBL producers or not. Stool, blood and urine samples were collected non repetitively from patients with fever and diarrhoea and were cultured on their respective appropriate media. Growths that occurred were transferred onto Nutrient agar for biochemical and serological identification using the standard methods. Antimicrobial susceptibility of the isolates was done using disc diffusion Kirby Bauer method. The isolates were tested for ESBL production using double disc diffusion method. Pulsed-Field Gel Electrophoresis (PFGE) was done on *Salmonella* isolates. Prevalence of all the isolates was 10.9 % ( 42/384) consisting of 5 *Salmonella Choleraesuis* (from stool samples), 4 *Salmonella Typhi* (3 from stool samples and 1 from blood sample) and 27 *Escherichia coli* (23 from urine samples and 4 from blood samples) and 6 *Klebsiella pneumoniae* (2 from blood samples and 4 from urine samples). All the bacterial isolates were susceptible to ceftriaxone, cefuroxime and cefotaxime. All the *Salmonella* isolates were also susceptible to ciprofloxacin and amoxicillin/clavulanic acid. There was high level of susceptibility of the other isolates to gentamycin (81.0%), ciprofloxacin (88.1%) and amoxicillin/clavulanic acid (73.8%). None of the 42 isolates was susceptible to ampicillin and tetracycline. None of the isolates produced ESBL. Pulsed-field gel electrophoresis showed that the 5 *Salmonella Choleraesuis* were similar in terms of DNA band size and separation while the 4 *Salmonella Typhi* also had the same genetic fingerprint.



## CHAPTER ONE

### 1.0 Introduction

*Salmonella* infection is a disease caused by a large group of bacteria of the genus *Salmonella* that affect man worldwide (Nesa *et al.*, 2012). It belongs to a family of Gram negative bacteria called enterobacteriaceae. These bacteria share some biochemical and genetical characteristics (Baylis *et al.*, 2011). They are oxidase-negative and ferment glucose with acid production. They are aerobes and facultative anaerobes (Baylis *et al.*, 2011). They are found in the intestinal tract of animals and man.

Some Gram-negative bacteria are responsible for causing food borne diseases, for example *Escherichia coli* and *Salmonella*. They also cause diseases in immunocompromised hosts, for example, *Escherichia coli*, *Salmonella* and *Klebsiella species* (Baylis *et al.*, 2011).

The diseases caused by *Salmonella* can be classified as non-typhoidal and typhoidal and paratyphoidal *Salmonella* infections (Baylis *et al.*, 2011). Non typhoidal salmonellosis can be defined as illnesses caused by all serotypes of *Salmonella* with the exception of *Salmonella Typhi*, *Salmonella Paratyphi A*, *Salmonella Paratyphi B* and *Salmonella Paratyphi C* (Smith *et al.*, 2005). While *Salmonella Typhi* causes typhoid fever, *Salmonella Paratyphi A*, *Salmonella Paratyphi B* and *Salmonella Paratyphi C* cause paratyphoid fevers (Tennant *et al.*, 2010). Both typhoid and paratyphoid fevers are termed enteric fevers (Crump *et al.*, 2015). In severe cases, *Salmonella* infection may spread from the intestine to the blood stream. On the other hand, non typhoidal *Salmonella* causes gastroenteritis (Crump *et al.*, 2015).

*Salmonella* has a worldwide distribution. Even though the true prevalence is unknown, it has been estimated that 93.8 million episodes with 155, 000 fatalities occur each year

(Majowicz *et al.*, 2010). Data from the World Health Organization Global Food-borne Infections network revealed *Salmonella Typhimurium* and *Salmonella Enteritidis* account for about 80% of all human isolates (Vieira *et al.*, 2009).

In Ghana, multi drug resistance development by Gram negative bacteria to commonly available antibiotics remains a major challenge for the health care system. The problem is compounded by the production of Extended-Spectrum Beta Lactamases (ESBLs). ESBLs are enzymes produced by certain bacteria types that are able to hydrolyze extended spectrum cephalosporins and are therefore effective against beta-lactam antibiotics (Ghafourian *et al.*, 2012). A study in Ghana showed that out of 405 bacterial isolates tested, 57.8% were ESBL producers (Feglo, 2011). In his study, 49.4% and 61.5% of the ESBL producing isolates were *Escherichia coli* and *Klebsiella species* respectively (Feglo, 2011).

In Half-Assini Government Hospital, culture systems for bacteriology started not long ago. Meanwhile, culture and sensitivity tests being conducted on bacteriological samples so far indicate high proportions of the isolates are detected to be resistant to many of the antibiotics tested including beta lactam antibiotics. Resistance to other antimicrobials like chloramphenicol, tetracycline and cotrimoxazole are also detectable (Personal observation).

### **1.1 Problem statement**

Many bacterial pathogens have been reported to have developed resistance to the commonly prescribed antibiotics in Ghana. Most of these studies have been done in Kumasi and Accra. It is also not known the bacterial types causing invasive infections in these areas but no such study was conducted in Half-Assini to determine the true state of affairs. As a border town, Half -Assini receives patients across the

border from La Cote d' Ivoire. This study is expected to generate data that can be compared with what pertains in the two big cities (Accra and Kumasi).

## **1.2 Justification**

Infections caused by *Salmonella* and other Gram-negative bacteria constitute heavy public health burden. They cause diseases like gastroenteritis, enteric fevers, pneumonia, urinary tract infections and meningitis in children leading to death (Crump et al., 2015). These enterobacteria can be transmitted by consuming food and water contaminated with human and animal faeces. Waste collection and disposal is a major problem facing residents of Half Assini, with no reliable source of water. Records from the Half- Assini Hospital show high fever and diarrhoea cases reporting to the hospital daily. Widal tests conducted on some of these patients are negative, necessitating the need for further investigations into the causes of fever and diarrhoea. This study was therefore undertaken to determine whether patients with fever and diarrhoea have *Salmonella* or other Gram negative bacteria as the aetiology. The study will also help in identifying whether *Salmonella* species causing the fever and diarrhoea show similar pattern distribution. The antimicrobial susceptibility pattern together with the beta lactamase production among the isolates would be determined.

## **1.3 Aim of the study**

To determine the prevalence and antimicrobial susceptibility of *Salmonella* and other Gram-negative bacteria isolates, together with whether they are ESBL producers, in Half

Assini Government- Hospital.

## **1.4 Objectives of the study**

- i. To culture blood and urine samples for *Salmonella* and other Gram-negative organisms.

ii. To culture stool samples for isolation of pathogenic enterobacteria. iii.

To perform antimicrobial susceptibility testing on the isolates obtained.

iv. To determine if the isolates obtained produce Extended Spectrum Beta Lactamase (ESBL).

v. To fingerprint the Salmonella isolates obtained.



## CHAPTER TWO

### 2.0 Literature review 2.1 The Salmonella organism




Fig. 2.1: Salmonella enterica

Source: [www.textbookofbacteriology.net/themicrobialworld/Salmonella.htm](http://www.textbookofbacteriology.net/themicrobialworld/Salmonella.htm) l (accessed February 2, 2014 at 13: 40 GMT)

*Salmonella* species are Gram-negative facultative anaerobic rods. They belong to the family of enterobacteriaceae. They are non- sporing and possess peritrichous flagella (as shown in Figure 2.1) for motility except *Salmonella Gallinarum* which possesses no flagella (Agbaje et al., 2011). They can be found in the environment and can infect man (Agbaje et al., 2011). *Salmonella* bacteria can survive for weeks in the environment. *Salmonella* can survive under harsh and dry conditions for a long period of time (Van Doren et al., 2013). They are not destroyed by freezing but their death is accelerated by heat at 55°C for ninety minutes or 60°C for twelve minutes (Sorrells et al., 1970).

Other Gram-negative bacteria are aerobes or facultative anaerobes. Some are motile (for example, *Escherichia coli*) while others are non-motile (for example, *Shigella species*).

They are oxidase negative and ferment glucose with acid production (Baylis et al., 2011).

Whilst some are regarded as food borne pathogens (for example *Yersinia enterocolitica* and

*Shigella* species), others are regarded as opportunistic pathogens especially in clinical settings, for example *Klebsiella species*, *Citrobacter* and *Serratia species* (Baylis et al., 2011).

## 2.2 Classification of Salmonella and other Gram negative organisms.

Gram-negative bacteria are broadly classified into two main groups based on their ability to ferment lactose, that is lactose-fermenting bacteria and non-lactose-fermenting bacteria (Agbaje et al., 2011). The genera of lactose-fermenting bacteria include *Escherichia*, *Klebsiella*, *Enterobacter* and *Citrobacter* while non lactose-fermenting genera are *Shigella*, *Proteus*, *Morganella*, *Salmonella* and many others (Agbaje et al., 2011).

The *Salmonella* organism can also be broadly classified into three groups based on host adaptability (Agbaje et al., 2011) and these are:

Group 1: *Salmonella* adapted to man. For example, *Salmonella Typhi*.

Group 2: *Salmonella* wholly or largely adapted to specific animal. For example, *Salmonella Dublin* in cattle, *Salmonella Gallinarum* in poultry, *Salmonella Abortusequi* in horses and *Salmonella Choleraesuis* in pigs.

Group 3: All other *Salmonella species* that are not host-adapted and produce infection in man.

For example, *Salmonella Typhimurium* and *Salmonella Enteritidis* (Agbaje et al., 2011).

The *Salmonella* organism can also be separated into three species; *Salmonella enterica*, *Salmonella bongori* and *Salmonella subterranea* (H.-M. Chen et al., 2013). *Salmonella enterica* is further divided into six species based on host range specificity and these are

i. *Salmonella enterica sub species enterica ii.*

*Salmonella enterica sub species salamae*

- iii. *Salmonella enterica sub species arizonae*
- iv. *Salmonella enterica sub species diarizonae*
- v. *Salmonella enterica sub species houtenae* and vi. *Salmonella enterica sub species indica* (H.-M. Chen et al., 2013)

Strains that are pathogenic to humans are in group one, that is *Salmonella enterica sub species enterica* (Crum-Cianflone, 2008). This group is further categorized into typhoidal and non-typhoidal *Salmonella* (Abdullahi et al., 2012). While the typhoidal *Salmonella* causes typhoid fevers (Martins et al., 2011), the non-typhoidal *Salmonella* causes gastroenteritis (Majowicz et al., 2010).

*Salmonella* nomenclature is based on the biotype, subspecies and serotype. For example, the *Salmonella* subspecies and serotype designation for typhimurium is *Salmonella enterica subspecies enterica serotype typhimurium*. This taxonomic designation was later changed to *Salmonella serovar Typhimurium*. The current and internationally accepted name is *Salmonella Typhimurium* (Velge et al., 2012).

### **2.3 Epidemiology and burden of *Salmonella* and other Gram negative bacterial infection**

*Salmonella* is an important public health problem globally (Egualé et al., 2015). *Salmonella* has a worldwide distribution although serovar distribution may be different in different countries and regions (Agbaje et al., 2011). Certain serovars show high liking for causing bacteraemia. However these serovars differ from one country to the other (Gordon et al., 2008; Kiratisin, 2008). Predominant *Salmonella* species causing infection are *Salmonella Typhimurium* and *Salmonella Enteritidis* (Yamatogi et al., 2015).

*Salmonella* causes majority of bacterial gastroenteritis worldwide (Majowicz et al., 2010). 94.3 million cases of gastroenteritis are reported globally each year with a case fatality of

155,000 (Majowicz et al., 2010). Annual estimated infections caused by *Salmonella* in United States stands at 1.2 million with 450 deaths (Boore et al., 2015).

In Ontario, investigations into non typhoidal *Salmonella* revealed that 2%-8% of the infection was associated with bacteraemia and extra intestinal focal infections (eg. arthritis, meningitis, pneumonia) occur in 5%-10% of those with bacteraemia (Matheson et al., 2010).

A study in Malaysia by Dhanoa and Fatt on 55 non-typhoidal *Salmonella* bacteraemic patients projected *Salmonella Enteritidis* as having the highest blood invasive potential (Dhanoa & Fatt, 2009).

It is estimated that, among hospitalised patients in Africa, case fatality for invasive nontyphoidal *Salmonella* have been between 4.4% and 27% in children and between 22% and 47% in adults (Gordon et al., 2008).

A study in Kenya revealed that infection with non typhoidal *Salmonella* occurred in 5.5% of children with a case fatality of 21% to 36% (Oneko et al., 2015). In Queen Elizabeth Central Hospital in Malawi, a study revealed that typhoid cases increased from fourteen per year between 1998 to 2010 to 843 in 2013 (Pitzer et al., 2015).

A study in Democratic Republic of Congo on suspected bacteraemic patients revealed that 1.4% was *Salmonella Typhi* and non typhoidal *Salmonella* accounted for 5.9% of the suspected cases (Kalonji et al., 2015). A retrospective study in Gambia showed that *Salmonella* bacteraemic case was 0.8% (106/13, 905) (Kwambana-Adams et al., 2015).

During 2003 and 2004 in South Africa, 1,138 cases of invasive non-typhoidal *Salmonella* were isolated and microbiologically confirmed out of which *Salmonella Typhimurium* and *Salmonella Enteritidis* accounted for 67% and 7% respectively.

In a study to determine the incidence of urinary tract infection in pregnant women in Nigeria, it came out that the incidence of *Escherichia coli* was 30% while that of *Klebsiella species* was 20.4% (Okonko et al., 2009).

In Ghana, it had been reported that the prevalence of enterobacteriaceae was 46.7% when research was conducted into the prevalence and associated risk factors of asymptomatic bacteriuria in ante-natal clients (Labi et al., 2015) whilst typhoid fever cases accounted for 3.2% of all infections recorded in three hospitals in Kumasi, Ghana (Saana et al., 2014).

#### **2.4 Age distribution and burden of infection caused by *Salmonella* and other Gram negative bacteria**

The infection with non-typhoidal *Salmonella* is mostly skewed towards the age extremes. A study conducted in Malawi showed that out of 2,517 children with non-typhoidal *Salmonella* bacteraemia, 85% were aged less than three years with estimated 19% to 35% of them being HIV positive (Gordon et al., 2008). In a study on non-typhoidal *Salmonella* infection in children relating age and infecting serotype, it has been reported that the predominant isolate was *Salmonella Typhimurium* isolated from people within the age bracket of two weeks to twenty years and that the chance of isolating *Salmonella* bacteria was high in the first three months of life (Asmar & Abdel-Haq, 2016).

In adults, there was a remarkable gender difference in the age at which the invasive disease acquisition occurs. In South Africa, invasive non-typhoidal *Salmonella* occurred in women at a younger age than men; a median age of 30 and 35 five years respectively (Feasey et al.,

2010). Similar results were recorded in Malawi with thirty three years for women and 37 for men with HIV as the major risk factor (Gordon et al., 2008).

A study in South Africa and Malawi showed a similar age distribution for the invasive disease in these countries; with a bimodal age distribution (Feasey *et al.*, 2010). A very low infection rate was also recorded in the first few months of life in Malawi (MacLennan et al., 2008) with 54% of the cases (2176/4044) seen in children below fifteen years while in South Africa, 32 % of the infection occurred under that same age (Feasey et al., 2010).

*Shigellae* and enterotoxigenic strains of *Escherichia coli* are important causes of diarrhoea associated morbidity and mortality in infants and children under five years (Lamberti et al., 2014)

### **2.5 Pathogenesis of *Salmonella***

*Salmonellae* can cause a range of important diseases in humans (Achouri et al., 2015). To cause infection, *Salmonella* is first ingested and pass through the digestive system to reach the small intestine (Velge et al., 2012). For disease to occur in healthy humans, an infectious dose of  $10^6$  *Salmonella* cells must be ingested (Chen et al., 2013). This infectious dose may be reduced to  $10^3$  *Salmonella* cells in elderly with low gastric acidity and individuals who use antacids (Raffatellu et al., 2006). However, higher infectious dose is associated with higher attack rate and shorter interval to bacteraemia (Crump et al., 2015).

*Salmonella* species penetrate and multiply within the host cell, including macrophages and epithelial cells (Figueira & Holden, 2012). To do this, the bacteria pass through the lacteals of the small intestine and enter the lymph node. They then gain entrance to the blood stream resulting in septicaemia.

*Salmonella* is transported to various tissues by hijacking phagocytic cells; the body's defence system, thereby evading destruction by macrophages (Velge *et al.*, 2012). The bacteria are also able to enter and invade the reticuloendothelial system, where they stay in the liver, spleen, bone marrow and lymph nodes (Raffatellu *et al.*, 2006).

The *Salmonella* bacteria continue to replicate until adequate density is reached after which they break out into the bloodstream to invade other parts of the body (Afroza, 2003). The bacteria then re-enters the gastrointestinal tract and re-infect the Peyer's patches and are shed in the stool (Afroza, 2003).

## **2.6 Clinical presentation of Salmonella and other Gram negative bacteria**

Clinical presentation of non-typhoidal *Salmonella* infection is not specific, both in children and adults (Crump *et al.*, 2015). Infection with *Salmonella* bacteria can be associated with fever, headache, diarrhoea, vomiting, splenomegaly and hepatomegaly, anorexia, malaise, dry cough and sore throat (Crump *et al.*, 2015).

Other Gram negative bacteria can cause urinary tract infections, blood stream infections, pneumonia caused by *Klebsiella pneumoniae* and intra abdominal infections (Paterson, 2006).

Incubation period of *Salmonella* and other Gram negative bacteria is dependent on the host immune response and the infectious dose (Acheson & Hohmann, 2001). The illness usually lasts for 4-7 days and in immunocompetent host, treatment is not usually needed because the person's immune system will overcome the infection. In addition, immunocompromised patients, infants and the elderly are likely to have a severe illness (Acheson & Hohmann, 2001).

Complications such as endovascular infection, deep bone or visceral abscesses and septic metastases may develop and they are difficult to treat (Acheson & Hohmann, 2001). Arthritis and septicaemia can also be caused by *Salmonella* (Dhanoa and Fatt, 2009b) and urinary tract infection (Jones et al., 2008) can also be caused by *Salmonella* and other Gram negative bacteria.

## **2.7 Antimicrobial susceptibility *Salmonella* and other Gram negative bacteria**

Multidrug resistance is described as resistance to three or more classes of antimicrobial agents as defined by the Clinical and Laboratory Standards Institute (CLSI) (Imanishi & Chai, 2013).

In United States, fluoroquinolones like ciprofloxacin and third generation cephalosporins (for example, ceftriaxone) are commonly used to treat severe *Salmonella* infections (Imanishi & Chai, 2013). According to the CDC, 38% of *Salmonella Enteritidis* and 21% of *Salmonella Typhimurium* were resistant to nalidixic acid. Again, 32% of *Salmonella Typhimurium* and 24% of *Salmonella Heidelberg* were resistant to ceftriaxone (Imanishi & Chai, 2013).

It has been reported that *Salmonella Typhi* and *Salmonella Paratyphi A* were all resistant to ampicillin. In the said study, *Salmonella Typhi* and *Salmonella Paratyphi A* showed 93.8% and 66.7% resistance to chloramphenicol. There was 100% susceptibility of the *Salmonella* bacteria isolates to ciprofloxacin (Abdullahi et al., 2012).

In Cote d'Ivoire, it was found that resistance of *Salmonella* isolates to amoxicillin-clavulanic acid was 58.1%. Again, 8.1% and 14% of the isolates were resistant to cefotaxime and chloramphenicol (Boni-Cissé et al., 2012). In Central African Republic, it was reported that in a study to determine the antimicrobial resistance in *Salmonella* isolates, the isolates were

highly susceptible to ciprofloxacin (98%) and gentamycin (97%) (Mossoro-Kpinde et al., 2015). According to them, resistance of *Salmonella* bacteria to four or five antibiotics is also common in Africa (Mossoro-Kpinde et al., 2015).

Resistance of other Gram negative bacteria especially *Klebsiella species* and *Escherichia coli* is of major concern. In their studies, Laxminarayan and his colleagues reported that resistance of enterobacteriaceae to carbapenem rose from 0.0% in 2001 to 1.4% in 2010, with *Klebsiella species* showing the highest resistance (Laxminarayan et al., 2016). They revealed that 71% of *Klebsiella species* and 50% of *Escherichia coli* were resistant to gentamycin (Laxminarayan et al., 2016). In the said study, nearly 100% of *Klebsiella species* were resistant to ampicillin (Laxminarayan et al., 2016).

A study in Nigeria on diarrhoeagenic *Escherichia coli* showed that the isolates were resistant to ampicillin and tetracycline (over 90%) and ciprofloxacin (7.2%) (Odetoyin et al., 2016). A gain, in Nigeria, a study showed that the resistance pattern of *Klebsiella pneumoniae* to beta lactam antibiotics, tetracycline and cotrimoxazole was 50% to 100% (Onanuga & Selekere, 2016).

A study in Tamale, Ghana to determine the antimicrobial susceptibility to *Escherichia coli* from drinking water in the metropolis showed high susceptibility of the isolates to ciprofloxacin (94.6%), gentamycin (91.1%) and ceftriaxone (89.3%) (Adzitey et al., 2015).

## **2.8 Epidemiology of bacteria expressing Extended Spectrum Beta Lactamase**

Extended spectrum beta lactamases are defined as enzymes produced by certain bacteria that have the ability to hydrolyse extended spectrum cephalosporins (Paterson & Bonomo, 2005). They are effective against beta-lactam containing antibiotics such as ceftriaxone, ceftazidime, cefotaxime and oxyimino-monobactam (Paterson & Bonomo, 2005). Enterobacteriaceae

producing ESBL have been implicated in numerous outbreaks of infection globally (Hijazi *et al.*, 2016). This enzyme is located on the plasmids of bacteria and it is transferrable among bacterial species (Rupp & Fey, 2003). It was first described in 1983 in Germany and England (Rupp & Fey, 2003). The prevalence of ESBL producing varies from one country to the other.

In a study to determine the prevalence of ESBL producing enterobacteriaceae in Germany, it was reported that 6.8% of the enterobacteriaceae were ESBL producers (Lübbert *et al.*, 2015). In Pakistan, it was reported that ESBL production in bacterial isolates was 0.7% (3/408) (Mahmood *et al.*, 2012).

Luvsansharav and his colleagues analysed faecal samples in Thailand and observed that 30%-50% of these subjects were ESBL carriers (Luvsansharav *et al.*, 2012). In a study in Iran undertaken between 2007 and 2008, 45% of *Klebsiella pneumoniae* from urinary tract infections were ESBL-producers (Ghafourian *et al.*, 2012).

A study showed that regular consumption of meat and chicken were significantly associated with high carriage rate of ESBL-producing enterobacteriaceae. ESBL production in this study was 24.8% (Hijazi *et al.*, 2016).

In Ethiopia, ESBL production was noted in *Escherichia coli* (28.6%) and *Klebsiella pneumoniae* (25.0%) (Mulisa *et al.*, 2015). In Lagos Teaching Hospital in Nigeria, 38 isolates with ESBL characteristics were identified. Out of this 55.3% were *Escherichia coli*, 31.6% were *Klebsiella pneumoniae*, 7.9% were *Proteus species* while *Morganella morganii* and *Clostridium freundii* each accounted for 1.6% (Mulisa *et al.*, 2015).

A study in an orphanage in Mali showed a very high prevalence where 63% of adults and

100% of the children were found to be carrying ESBL-producing Enterobacteriaceae (Tandé et al., 2009). This was however different in Akwatia, Ghana where a study showed that no Salmonella isolates produced ESBL(Dakorah, 2014). A study in Korle Bu Teaching Hospital in Ghana, however, reported that 49.3% of 300 Enterobacteria isolates were ESBL producers (Obeng-Nkrumah et al., 2013).

## **2.9 Transmission of Salmonella and other Gram negative bacteria**

Transmission of Salmonella and *Escherichia coli* is predominantly through the consumption of contaminated foods and water with the faeces of man (Crump et al., 2015). Infection also can be contracted from sources like undercooked or incorrectly prepared poultry and infected eggs (Upadhyaya et al., 2015), reptiles such as turtles, snakes and lizards which carry the bacteria in their intestine (Lukac et al., 2015) and contaminated fruits and vegetables (Raja et al., 2015). Direct transmission from person-to-person can also occur through certain types of sexual contact as in oral-anal contact (Quinn, 2015).

According to Acheson and Hohmann, Salmonella infection can be through contacts with infected pets, nosocomial transmission, waterborne transmission and contaminated drugs and solutions (Acheson & Hohmann, 2001).

Acquisition of *Escherichia coli* infection can be through person-to-person through direct contact or faecal-oral route or by contaminated food or water (Scott, 1990)

Other Gram-negative organisms like *Citrobacter*, *Enterobacter species*, *Serratia marcescens*, *Klebsiella species* and *Proteus species* can be transmitted by the health care givers (Bagattini et al., 2006).

## **2.10 Risk factors for transmission of *Salmonella* and other Gram negative bacteria**

Risk factors for transmission of *Salmonella* can be categorised into:

- i. Environmental risk factors and
- ii.

Host risk factors

### **2.10.1 Environmental risk factors for transmission of *Salmonella***

#### **2.10.1.1 Food and water as a risk factor for transmission of *Salmonella***

Transmission of *Salmonella* can be through oral-faecal route. The occurrence is high in the rainy season where food and water become contaminated due to flooding, suggesting that environmental risk factors are important in the spread of the infection (Kariuki et al., 2006; Milledge et al., 2005). Meat, egg, chickens and dairy products have been implicated as vehicles for transmission of the bacteria (Schlundt *et al.*, 2004). The bacteria have been isolated from goats, sheep, cattle and pigs; hence undercooking of these products can serve as a vehicle for transmission (Schlundt *et al.*, 2004).

#### **2.10.1.2 Zoonosis as a risk factor for transmission of *Salmonella* and Gram negative bacteria**

Infected animals like turtles and chicken put individuals at risk of infection (Gordon, 2008). Lizards and snakes can also serve as a vehicle for transmission (Lukac et al., 2015). Handling of chicken by children is a well established risk factor for acquisition of *Salmonellae* (CDC, 2007).

#### **2.10.1.3 Nosocomial risk factors for transmission of *Salmonella* and other Gram negative bacteria**

Nosocomial infections are described as diseases or infections that originate or are acquired in the hospital. Nosocomial infection of *Salmonella* and *Klebsiella species* can be severe in developing countries where most of the children are malnourished or have other host risk

factors (Morpeth *et al.*, 2009). Inability or improper hand washing by health care providers exposes their patients to the risk of infection (Morpeth *et al.*, 2009).

Failure to accurately sterilise reusable materials also predisposes the patients to infection.

## **2.10.2. Host risk factors for transmission of *Salmonella* and other Gram negative bacteria**

### **2.10.2.1 Age as a risk factor for transmission of *Salmonella* and other Gram negative bacteria**

Extremes of age, that is children less than three months and adults above fifty years of age are at risk of infection (Matheson *et al.*, 2010). In African population, old age is a risk factor for *Salmonella* (Morpeth *et al.*, 2009). This is because children's immunity is not fully developed while old age is associated with waned immunity.

### **2.11.2.2 Exposure to antimicrobial agents as a risk factor for transmission of *Salmonella***

Wrong use of antibiotics without prescription, not following prescribed instructions predisposes one to infection caused by *Salmonella* and other Gram negative bacteria (Morpeth *et al.*, 2009). Recent use of antibiotic is a risk factor for development of diarrhoea caused by *Salmonella* (Mabey *et al.*, 1987). Endogenous bowel flora alteration as a result of surgery or antimicrobial therapy with loss of mucosal integrity is a predisposing factor (Morpeth *et al.*, 2009).

### **2.10.2.3 Achlorhydria as a risk factor for transmission of *Salmonella* and other Gram negative bacteria**

*Salmonella* cannot survive at a gastric acidic content of less than 2.5 (Tennant *et al.*, 2011). Gastric acid secretion has been shown to be reduced during acute enteric fever (Crump *et al.*, 2015). It can therefore be said that gastric hypoacidity in infants or caused by medications is a predisposing factor for gastrointestinal infection, including the nontyphoidal *Salmonella* (Gendrel *et al.*, 1994).

#### **2.10.2.4 Malaria infestation as a risk factor for transmission of *Salmonella* and other Gram negative bacteria**

Malarial disease predisposes an individual to infection with non typhoidal *Salmonella* (Graham *et al.*, 2000). Malaria has been suspected to increase the risk of non typhoidal *Salmonella* infection (Morpeth *et al.*, 2009). Malaria can lead to haemolysis which impairs macrophage and neutrophil function. People with malaria are predisposed to *Salmonella* infection (Ao *et al.*, 2015). The haemolysis leads to increased iron availability to the non-typhoidal *Salmonella*.

#### **2.10.2.5 Malnutrition as a risk factor for transmission of *Salmonella* and other Gram negative bacteria**

Malnutrition leads to reduction in the immune system. Children relatively grow healthier when they are well-fed. Malnourished people are at increased risk of infection with *Salmonella* and other Gram negative bacteria (Ao *et al.*, 2015).

#### **2.10.2.6 HIV infection as a risk factor for transmission of *Salmonella* and other Gram negative bacteria**

HIV infection leads to suppression of immune system. HIV infected individuals have a higher chance of contracting *Salmonella* and other Gram negative bacteria (Ao *et al.*, 2015). *Salmonella* bacteraemia is more common in HIV-infected individuals (Graham *et al.*, 2000).

#### **2.11.0 Prevention of infection caused by *Salmonella* and other Gram negative bacteria.**

Medical treatment is needed in severe cases so as to prevent environmental contamination with infected faecal materials. (Crump *et al.*, 2015). Personal sanitation can help prevent the infection with *Salmonella* and other Gram negative bacteria including *Klebsiella pneumoniae*, *Escherichia coli*, *Citrobacter* and *Enterobacter*. Using poultry as pets should

be discouraged (Behraves et al., 2014). Thorough and proper hand washing with soap and copious amount of water prior to eating or before preparation of food, as well as after visiting the toilet, changing diapers, and after touching pets or other animals can help prevent infection with *Salmonella* and other Gram-negative bacteria (Ellingson et al., 2014) and other Gram negative bacteria (Wilson *et al.*, 2016).

## **2.12 Other Gram negative pathogens**

### **2.12.1 *Pseudomonas aeruginosa***

*Pseudomonas aeruginosa* is a Gram-negative, non-sporing aerobic rod (Ryan and Ray 2004). It is found in the intestinal tract, soil, water, moist environment and sewage. *Pseudomonas aeruginosa* is primarily identified by its grape-like odour it produces on bacteriological medium. It can be grown under laboratory condition at 42°C (Ryan & Ray, 2004).

It is an opportunistic pathogen and causes diseases in immunocompromised hosts. It can infect burns, wounds, urinary tract can also cause blood infections. It is diagnosed by its grape-like odour on bacteriological medium. It is oxidase and catalase positive (Srinivasan *et al.*, 2003).

*Pseudomonas* is resistant to a wide range of antibiotics. However, aminoglycosides, monobactams and polymyxins can be used to treat infections caused by *Pseudomonas aeruginosa* (Hachem *et al.*, 2007).

### **2.12.2 *Shigella species***

*Shigella* is a Gram-negative, facultative anaerobic rod. It is non-motile and non-spore forming organism. They are naturally found in the intestinal tract of man (Baylis *et al.*, 2011). *Shigella species* are classified into four serogroups based on their antigenic structure and biochemical reactions (Ansaruzzaman *et al.*, 1995). The groups are:

Serogroup A: *Shigella dysenteriae*

Serogroup B: *Shigella flexneri*

Serogroup C: *Shigella boydii*

Serogroup D: *Shigella sonnei* .

*Shigella* can be transmitted by faecal-oral route. For infection to occur, less than 100 bacteria cells are required (Mounier *et al.*, 1992). The *Shigella species* invade the epithelia of the small intestine (Mounier *et al.*, 1992) and replicate; spreading to neighbouring epithelia cells resulting to tissue destruction (Suzuki & Sasakawa, 2001).

The most common clinical manifestations are diarrhoea, vomiting, fever and nausea.

Diagnosis is made by isolating the bacteria in fresh faecal sample cultures. They are nonmotile and non-lactose fermenters except *S. sonnei* (Ito *et al.*, 1991). Infection with *Shigella* can be prevented by frequent hand washing and cooking all foods before eating (Ram *et al.*, 2008).

### **2.12.3 *Escherichia, Klebsiella, Citrobacter and Enterobacter***

The genera *Escherichia, Klebsiella, Citrobacter and Enterobacter* are collectively referred to as coliform bacteria. They are lactose-fermenters. They cause disease in immunocompromised hosts. *E. coli* is the most commonly isolated coliforms in the hospitals. They are all motile except *Klebsiella*. Choice of antibiotics is determined by the isolates circulating in a particular institution (Ryan & Ray, 2004).

### **2.13.4 *Vibrio***

The genus *Vibrio* is a Gram-negative bacteria comma shaped rods (Thompson *et al.*,

2005). They are motile, aerobes and found in aquatic environment. It is associated with undercooked foods. Pathogenic *Vibrio species* include *V. cholera*, *V. parahaemolyticus* and *V. vulnificus*. Transmission is by contaminated water or food.

# KNUST



## **CHAPTER THREE**

### **3.0 Materials and methods 3.1 The study area**

Half Assini is the district capital for Jomoro District. The District is located in the SouthWestern part of the Western Region. It shares boundaries with Aowin-Suaman District to the North, the Gulf of Guinea to the South, the Ellembele District to the East and the Republic of La Cote D'Ivoire to the West. The District has a population of 150,107 and an annual growth rate of 3%.The indigenes are Nzemas. The District shares boundary with Republic of La Cote d' Ivoire. The major occupations of the people are farming, fishing and trading.

### **3.2 Ethical approval**

Ethical approval was sought from a joint committee of Komfo Anokye Teaching Hospital and School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, before the commencement of the study.

### **3.3 Study patients**

The study subjects were patients who visited the hospital with fever and diarrhoea irrespective of their country of origin, age, gender, socio economic status or religion.

Informed consent was obtained from the patients after the essence and the procedure of the study was explained to them in a language they understood, sometimes with the assistance of an interpreter.

#### **3.3.1 Inclusion criteria of the study patients**

Any patient with fever and diarrhoea visiting Half Assini Government Hospital who consented to be part of the study had their samples included. Children's consent was obtained through their parents or guardians.

### 3.3.2 Exclusion criteria of the study patients

Patients taking antibiotics prior to the specimen collection were excluded from the study. This is because the antibiotics can have either bactericidal or bacteriostatic effect thereby preventing the growth of the bacteria on the artificial medium, resulting to false negative result. Patients who refused to be included in the study were not also enrolled even though they were having fever and diarrhoea.

### 3.4 Informed consent

The purpose of the study was explained to the patients. Samples were only collected after the patients understood the purpose of the investigation and consented in writing to partake in it. Patients who declined to participate were excluded from the study.

### 3.5 Determination of sample size for the study

A total of 384 non repetitive urine, stool and blood samples were collected for the study. In calculating this sample size, the formula  $n = \frac{Z^2(P)(1-P)}{d^2}$  was used where

- i.  $Z(1.96)$  was the standard score for the confidence level of 95%.
- ii.  $P$  was the sample proportion or prevalence of the disease or bacterial isolates under investigation.
- iii.  $d(5\%)$  was the allowable error,  $=0.05$  (Naing et al., 2006).

0.5 was used to represent the 'P' since the value was not known and could not be estimated (Lwanga & Lemeshow, 1991).

Therefore, sample size  $(n) = \frac{1.96^2 \times (0.5) \times (1-0.5)}{0.05^2} = 384$  samples

Therefore, a sample size of 384 was used for this study.

### **3.6 Sample type**

Blood, urine and stool were collected at Half Assini Government Hospital Laboratory between the period of March 3, 2014 and October 31, 2015. The samples were collected from the patients using non probability consecutive sampling method where only those who visited the hospital with fever and diarrhoea during the study period were enrolled into the study.

### **3.7 Isolation and identification of Salmonella and other Gram-negative bacteria**

#### **3.7.1 Media used in the isolation and identification of Salmonella and other Gram- negative bacteria**

To culture, isolate and identify the Salmonella and other Gram-negative bacteria from stool, blood and urine, various bacteriological media were used. These are Brain heart infusion broth, Selenite F broth, Blood agar, MacConkey agar, Salmonella-Shigella agar, Cystine Lactose Electrolyte Deficient (CLED) agar, Urea agar, Nutrient agar, Mueller Hinton agar, Triple Sugar Iron agar, Motility-Indole-Ornithine (MIO) agar, Citrate agar and Peptone water.

The preparation of these media is shown in Appendix 3.7.1A. The manufacturer's instructions were strictly followed in the preparation of the media. The prepared media were dispensed as in Appendix 3.7.1B.

### **3.8 Quality control of the prepared media**

Quality control was performed to determine sterility and performance of various media employed in the isolation of the organisms, by performing sterility testing and performance testing.

### **3.8.1 Sterility testing of the prepared media**

This was done by incubating 3 of each batch of 30 plates aerobically at 37°C for 2 days to determine if autoclaving was adequate. If more than two colonies were seen per plate, the whole batch was discarded.

### **3.8.2 Performance testing of the prepared media**

This was done by inoculating the media with appropriate stock culture using standard inoculating procedure using control organism of *Escherichia coli* ATCC 25922 to determine if they grew well and produced the desired growth characteristics.

## **3.9 Samples collection for isolation of Salmonella and other Gram negative bacteria**

### **3.9.1 Blood sample collection**

After disinfecting the site of venepuncture using 70% alcohol, about 5ml of the blood was taken from the patients and aseptically dispensed into blood culture bottle containing 15ml of brain heart infusion broth.

#### **3.9.1.1 Incubation of the blood culture bottle**

The broths were incubated aerobically at 37°C for 7 days, but inspected twice daily for signs of microbial growth such as haemolysis, turbidity, coagulation of the broth, a floccular deposit on top of the broth and a surface pellicle. The first subcultures were done on Blood agar and MacConkey agar after overnight of incubation of the broth. The

Blood agar and MacConkey agar plates were then incubated at 37°C aerobically overnight. The final subcultures were done on the seventh day and incubated overnight.

After the overnight incubation, the plates were inspected for growth.

### **3.9.2 Stool sample collection for isolation of pathogenic enterobacteria**

Stool samples were received in clean, leak proof containers with tight fitting lids. The collected stool samples were immediately inoculated into Selenite F broth. The broths were

then incubated overnight at 37°C aerobically. The broths were sub cultured onto Salmonella-Shigella agar and incubated aerobically at 37°C for 24 hours. After the overnight incubation, the plates were inspected for growth. Pale lactose non-fermenting colonies were looked for.

### 3.9.3 Urine sample collection

Clean-catch mid-stream urine samples were collected from the patients. The patients were advised to produce and collect urine sample as aseptically as possible. They were instructed to void the first parts of the stream and the remaining mid stream urine was collected into sterile containers given to them. The urine samples were then cultured immediately on Cystine lactose electrolyte deficient (CLED) agar using a calibrated loop of 1/500ml (0.002ml) and incubated aerobically at 37°C overnight. After the overnight incubation, the plates were inspected for growth. Growths that occurred were counted to determine whether there was significant growth or not. Plates with 19 or less colonies (equivalent to  $10^4$  or less organisms) were considered insignificant and were not followed up. The test was repeated when the colony count was between  $10^4$  and  $10^5$ . However, plates with colonies more than  $10^5$  were followed up and identified.

### 3.10 Identification of *Salmonella* and Gram negative bacteria

The following procedures were followed in isolating and identifying any bacterial growth on the media:

- i. Colonial morphology
- ii. Gram reaction
- iii. Biochemical reactions
- iv. Serology

(not used for the isolation of *Klebsiella pneumoniae* and *Escherichia coli*)

- v. Analytical Profile Index (API), (protocol as shown in Appendix 3.10).

The following tests were also carried out:

- i. Antimicrobial sensitivity test on the isolates using the Kirby-Bauer method.
- ii. Double disc diffusion test to determine if the isolates were ESBL producers or not
- iii. Pulsed-Field Gel Electrophoresis was carried out to determine genetic fingerprint of the isolates.

### **3.11 Colonial morphology for identification of *Salmonella*, *Escherichia coli* and *Klebsiella pneumoniae***

Identification of the growths on agar plates was performed using their growth characteristics on their various culture plates. While *Salmonellae* were non-lactose fermenters, *Klebsiella* and *E. coli* were fermenters of lactose. The growths were then picked and Gram staining was done on them. *Salmonella*, *Klebsiella* and *E. coli* were Gram negative rods. They were further identified using biochemical and sugar fermentation tests. The isolates so identified had their identification confirmed using the API.

### **3.12 Identification of the organism using biochemical reactions**

#### **3.12.1 Urease test**

The test was done by inoculating the test organism in a bijou bottle containing 3ml of solidified urea agar and incubated aerobically at 37°C for up to 12 hours.

*Salmonella* and *Escherichia coli* are non-urease producing organisms; hence there was no change in the original colour of the medium. *Klebsiella pneumoniae* is a urease producer, changing the colour of the medium from initial orange to pink. This test was used to separate *Klebsiella* from *Salmonella* and *Escherichia coli*.

#### **3.12.2 Motility, indole and ornithine decarboxylase test for the identification of the isolates**

### **a. Motility**

The motility test was done by inoculating motility-indole-ornithine medium with the test organism using a sterile straight wire. The set-up was incubated aerobically at 37°C overnight. *Salmonella* (except *Salmonella Gallinarum*) and *Escherichia coli* were motile indicating positivity by exhibiting cloudiness of the medium or growth spreading from the line of inoculation into the entire medium. Non-motile organisms, as was the case for *Klebsiella pneumoniae* grow only along the line of inoculation, leaving the surrounding medium clear, indicating a negative result. This test was used to differentiate *Klebsiella pneumoniae* from *Salmonella* and *Escherichia coli*.

### **b. Indole test**

The test was done by inoculating the test organisms into motility-indole-ornithine medium and incubating aerobically at 37°C overnight. After overnight incubation, three drops of Kovac's reagent were added and shaken to mix. A pinkish surface layer indicated indole positivity while non-pinkish layer indicated that the organism was not indole producer. *Escherichia coli* were positive to the test while *Salmonella species* and *Klebsiella pneumoniae* were non-indole producers.

### **c. Ornithine decarboxylase production test**

*Salmonella species* (except *Salmonella Typhi* and *Salmonella Gallinarum*) and *Escherichia coli* possess the enzyme ornithine decarboxylase that removes the carboxyl group from the ornithine to indicate a positive test. This was indicated by the turbid purple coloration of the medium. *Klebsiella pneumoniae* lacks this enzyme, so gives a negative result which shows as yellow coloration at the bottom of the medium. The test was done by inoculating the motility-indole-ornithine medium with the test organism and incubated aerobically at 37°C overnight.

### 3.12.3 Triple sugar iron (TSI) agar

The test was done by stabbing the butt with the test organism and streaking the slant. The inoculated medium was incubated aerobically at 37°C overnight with the cap loosely closed. The reaction suggestive of non-typhoidal *Salmonella species* was alkaline slant/acid butt, gas and Hydrogen sulphide production. A reaction suggestive of *Salmonella Typhi* was alkaline slant/acid butt with small amount of H<sub>2</sub>S production. Reaction of both *Klebsiella pneumoniae* and *Escherichia coli* in TSI medium was slant/acid butt, gas production, with no Hydrogen sulphide produced.

### 3.12.4 Citrate utilisation test

*Klebsiella pneumoniae* was citrate positive. This was exhibited as a growth and a blue colouration of the medium. *Escherichia coli* was however negative to this test. This was used to separate *Klebsiella pneumoniae* from *Escherichia coli*. The test was done by inoculating the test organism in a bijou bottle containing the citrate agar and incubated aerobically overnight at 37°C.

### 3.13 Serologic test for suspected *Salmonella* isolates

Two separate drops of normal saline were placed on a clean labeled glass slides. A small part of the suspected *Salmonella* colony from overnight nutrient agar culture plate was picked and thoroughly mixed with each drop of the normal saline to obtain a smooth suspension. Drop of antisera was added to one of the bacterial suspensions on the slide. To the other drop was added a normal saline to rule out auto agglutination. Both the antisera with the bacterial suspension and the normal saline with the bacterial suspension were mixed each with a sterile loop. The slides were gently tilted back and forth for 1 minute and agglutination was looked for.

When agglutination was observed for the bacterial suspension with group 'O' polyvalent antiserum, it was repeated for the polyvalent 'H' antiserum. Then the set up was repeated for group specific antisera. The group specific *Salmonella* isolates were then confirmed using API.

### **3.14 Antimicrobial susceptibility testing**

To perform this test, three isolated colonies were touched using a sterile wire and emulsified in 4 mls of sterile peptone water. The turbidity was matched with 0.5 McFarland. Using a sterile swab, a Mueller Hinton agar was inoculated by dipping the swab into the inoculum and streaking the swab all over the surface of the medium. With the lid closed, 5 minutes was allowed before the antibiotic disc was placed on the Mueller Hinton agar using sterile forceps for the following antibiotics: Ampicillin (10 $\mu$ g),

Tetracycline (10 $\mu$ g), Cotrimoxazole (25 $\mu$ g), Gentamycin 10 $\mu$ g), Cefuroxime (30 $\mu$ g), Chloramphenicol (10 $\mu$ g), Ceftriaxone (30 $\mu$ g), Cefotaxime (30 $\mu$ g) amoxicillin/clavulanic acid [(20 $\mu$ g+10 $\mu$ g)] and ciprofloxacin. The plates were then incubated aerobically at 37°C overnight.

Using a ruler, the diameter of the zone of inhibition was measured and compared to a set of standard chart to determine if the organisms were susceptible, resistant or intermediately susceptible depending on the diameter of the zone of inhibition produced by the organism.

### **3.15. Detection of Extended Spectrum Beta Lactamase using double discs diffusion method**

Three isolated colonies were inoculated into 1% peptone water and the turbidity was adjusted to 0.5 McFarland. The test organism was streaked onto the Mueller Hinton agar. With the lid closed, 5 minutes was allowed before the discs [(cefotaxime (30 $\mu$ g) and amoxicillin/clavulanic acid (20 $\mu$ g+10 $\mu$ g)] were placed onto the inoculated Mueller Hinton, 25mm apart centre to centre. The plate was then incubated aerobically at 37°C overnight.

### **3.15.1 Interpretation of the double discs diffusion test**

After the overnight incubation, if the diameter of the zone of inhibition is extended towards the clavulanic acid disc, then the organism was identified as an ESBL producer, hence ESBL positive.

KNUST

### **3.16 Pulsed-Field Gel Electrophoresis (PFGE) of the Salmonella isolates**

The test was performed by making a suspension of Salmonella isolates from a fresh overnight culture, not more than 18 hours old, in cell suspension buffer to a turbidity of 0.70 using Dade Behring Microscan turbidity meter. One percent molten SeaKem Gold agarose was added to the cell suspension and allowed to solidify as a plug. The plug was immersed in lysis buffer containing XbaI restriction enzyme. The plug was lysed using lysis buffer to expose the genomic DNA. Restriction enzyme XbaI was used to cut the DNA into fragments at specific restriction sites. Slice was prepared and attached to tooth comb and placed in the electrophoresis chamber of BIORAD CHEF-DR electrophoresis system for electrophoresis. After the electrophoresis, the agarose gel was stained using Ethidium bromide and the image of the DNA finger print was captured using BIORAD gel documentation system. Salmonella Braenderup [H9812] was used as a control. PFGE was performed according to protocol developed Pulse Net international (Ribot et al., 2001).

### **3.17 Data analysis**

Data generated in the study were presented in summary tables and analysed statistically. The statistical analysis was performed using Microsoft excel and Statistical Package for the Social Sciences (SPSS) version 18. Most variables were categorical or continuous.

Continuous variables were presented as mean  $\pm$  standard deviation and the categorical data were presented as proportions. The continuous data were compared to each other using chi-square tests. To assess the level of significance of an assumed hypothesis, Pearson chi square test ( $P < 0.05$ ) was employed.

KNUST

## CHAPTER FOUR

### 4.0 Results

#### 4.1: Age, gender and religion of the study patients

A total of 384 patients of all ages, gender, religious beliefs and occupational status were screened for non typhoidal Salmonella and other Gram negative bacteria. Out of the 384 patients who visited the hospital with fever and diarrhoea and chosen for the study, 140 representing 36.5% were under five years. Two hundred and forty nine (64.8%) were females compared to 135 (35.1%) males (as shown in Table 4.1). As low as 26 (6.8%) subjects were Moslem, with 358 (93.2%) being Christians (Table 4.1).




Table 4.1: Demographic characteristics of the study patients stratified by the bacterial isolates.

| Demographic characteristics |                          | Bacterial isolates        |                |                     |              | P value              |                      |                      |
|-----------------------------|--------------------------|---------------------------|----------------|---------------------|--------------|----------------------|----------------------|----------------------|
|                             |                          | Salmonella isolates (n=9) | E. coli (n=27) | K. pneumoniae (n=6) | Total (n=42) | P value <sup>x</sup> | P value <sup>y</sup> | P value <sup>z</sup> |
| Mean age (years)            |                          | 31.1±26.3                 | 30±23.6        | 22±18.0             | 29.1±22.9    | 0.16                 | 0.59                 | 0.14                 |
| Gender                      | M (n=135)                | 2 (22.2%)                 | 11(40.7%)      | 1(16.7%)            | 14(33.3%)    | 0.32                 | 0.79                 | 0.27                 |
|                             | F (n=249)                | 7(77.8%)                  | 16(59.6%)      | 5(83.3%)            | 28(66.7%)    |                      |                      |                      |
| Sample type                 | Blood (n=384)            | 1(11.1%)                  | 4(14.8%)       | 2(33.3%)            | 7(16.7%)     | 0.17                 | 0.79                 | 0.16                 |
|                             | Stool (n=384)            | 8(88.9%)                  | 0(0%)          | 0(0%)               | 8(19.0%)     |                      |                      |                      |
|                             | Urine (n=280)            | 0(0%)                     | 23(85.2%)      | 4(66.7%)            | 27(64.3%)    |                      |                      |                      |
| Country                     | Ghana (n=368)            | 9(100%)                   | 26(96.3%)      | 6(100%)             | 41(97.6%)    | 0.56                 | N/A                  | 0.63                 |
|                             | La Cote d' Ivoire (n=16) | 0(0%)                     | 1(3.7%)        | 0(0%)               | 1(2.4%)      |                      |                      |                      |
| Religion                    | Christian (n=358)        | 8(88.9%)                  | 26(96.3%)      | 6(100%)             | 40(95.4%)    | 0.40                 | 0.40                 | 0.63                 |
|                             | Moslem (n=26)            | 1(11.1%)                  | 1(3.7%)        | 0(0%)               | 2(4.8%)      |                      |                      |                      |
| Educational status          | Tertiary (n=26)          | 1(20%)                    | 0(0.0%)        | 1(16.7%)            | 2(4.7%)      | 0.19                 | 0.11                 | <b>0.04</b>          |
|                             | SHS (n=43)               | 0(0%)                     | 7(25.9%)       | 0(0.0%)             | 7(16.7%)     |                      |                      |                      |

|  |                |        |           |          |           |
|--|----------------|--------|-----------|----------|-----------|
|  | JHS (n=33)     | 1(20%) | 1(3.7%)   | 1(16.7%) | 3(7.1%)   |
|  | Primary (n=73) | 1(0%)  | 2(7.4%)   | 3(50%)   | 6(14.3%)  |
|  | Others (n=9)   | 0(0%)  | 0(0.0%)   | 0(0.0%)  | 0(0.0%)   |
|  | None (n=200)   | 6(60%) | 17(63.0%) | 1(16.7%) | 24(57.1%) |

Key: P= Used to determine level of significance, P value<sup>x</sup> = Salmonella isolates vrs *E. coli*, P value<sup>y</sup> = Salmonella isolates vrs *K. pneumoniae*, P value<sup>z</sup> = *E. coli* vrs *K. pneumoniae*, Salmonella isolates= Salmonella Choleraesuis and Salmonella Typhi, N/A= Not applicable, : M= Male, F=Female, n=total number, SHS=Senior High School, JHS= Junior High School, , Others=Crèche, Day care, Nursery or Kindergarten, None= No formal education

#### 4.2 Bacterial isolates and the samples from which they were isolated

There were twenty seven (27) *Escherichia coli* isolated; 4 (14.8%) were obtained from blood and 23(85.2%) were isolated from urine. No *Salmonella* pathogen was isolated from urine. All the *Salmonella Choleraesuis* (5) were isolated from stool samples. One *Salmonella Typhi* out of the four isolates was isolated from blood and the rest were from stool. Whilst two (2) *Klebsiella pneumoniae* were isolated from blood samples, 4 were from urine samples. The total number of isolates obtained from blood sample was 7 (16.67%) consisting of 4 *E. coli*, 2 *Klebsiella pneumoniae* and 1 *Salmonella Typhi*. Five *Salmonella Choleraesuis* and 3 *Salmonella Typhi* were also obtained from stool. Twenty seven isolates comprising of 23 *Escherichia coli* and 4 *Klebsiella pneumoniae* were isolated from urine sample as shown in Table 4.2. There were no significant differences observed among the isolates from various sample types when *Salmonella* isolates and *Escherichia coli* were compared (P =0.17) and when *Salmonella* isolates and *Klebsiella pneumoniae* were compared (P=0.79). There was also no significant difference (P=0.16) when *Escherichia coli* and *Klebsiella pneumoniae* were compared as shown in Table 4.1.

Table 4.2: Proportions of positive bacteria isolated

| Bacteria isolates | Frequency | Percentage |
|-------------------|-----------|------------|
|-------------------|-----------|------------|

|                                |    |      |
|--------------------------------|----|------|
| <i>Salmonella Choleraesuis</i> | 5  | 11.9 |
| <i>Salmonella Typhi</i>        | 4  | 9.5  |
| <i>Escherichia coli</i>        | 27 | 64.3 |
| <i>Klebsiella pneumoniae</i>   | 6  | 14.2 |

Table 4.3: Bacterial isolates and the samples from which they were isolated

| Sample type   | <i>S. Choleraesuis</i> | <i>S. Typhi</i> | <i>Escherichia coli</i> | <i>Klebsiella pneumoniae</i> |
|---------------|------------------------|-----------------|-------------------------|------------------------------|
| Blood(7/384)  | 0                      | 1               | 4                       | 2                            |
| Urine(27/280) | 0                      | 0               | 23                      | 4                            |
| Stool(8/384)  | 5                      | 3               | 0                       | 0                            |

#### 4.3 Prevalence of Salmonella and other Gram negative bacteria

The bacterial isolates were isolated from 42 patients representing 10.94%. Out of the 42 bacterial isolates, 5(11.9%) were *Salmonella Choleraesuis*, 4 (9.5%) were *Salmonella Typhi*. There were 27(64.3%) *Escherichia coli* and 6(14.3%) *Klebsiella pneumoniae* isolates (Table 4.2).

#### 4.4 Bacterial isolates and gender of the study patients

All the *Salmonella Choleraesuis* isolates were from females. *Salmonella Typhi* isolates were evenly distributed among the males and females. Twenty seven (27) patients were infected with *Escherichia coli* out of which sixteen (16) (60.0%) were females and eleven (11) (40.7%), being males (as shown in table 4.1 above). There was no significant difference between the male and female patients infected with Salmonella isolates and

*Escherichia coli* (P=0.32). No significant difference was also recorded when *Salmonella* isolates and *Klebsiella pneumoniae* were compared (P=0.79). So also was there no significant difference when *Escherichia coli* and *Klebsiella pneumoniae* were compared (P=0.27) as shown in Table 4.1.

#### **4.5 Bacterial isolates and country of origin of the study patients**

Table 4.1 shows that three hundred and sixty eight (368) of the subjects, representing 95.8% came from Ghana. Those subjects who came from La Cote d' Ivoire were 4.2%. All the *Salmonella* isolates were isolated from Ghanaian subjects. There was however no significant difference in the country of origin of the patients when *Salmonella* isolates and *Escherichia coli* were compared (P=0.56) and also when *Escherichia coli* and *Klebsiella pneumoniae* were compared (P=0.63).

#### **4.6 Bacterial isolates and the religion of the study patients**

Patients for this study came from two main religions denominations: Christianity and Moslem. No patient from other religion was recorded. There was no *Salmonella Choleraesuis* and *Klebsiella pneumoniae* isolates obtained from the Moslems (Table 4.1). Whilst Christians accounted for 93.2% of the patients visiting the Half Assini Government Hospital, those with Islamic faith were 6.8%. There was significant difference in the religion of the study patients infected with the bacterial pathogens.

#### **4.7 Bacterial isolates and educational status of the study patients**

About 52% of the patients who took part in this study had no formal education; 6.8% (26) of the patients were educated up to tertiary level. Twenty four (57.1%) of the isolates were isolated from those patients with no formal education, with none isolated from the educational group named 'others'. There was no significant difference in the educational

status of the patients infected with bacterial isolates when *Salmonella* isolates and *Escherichia coli* were compared (P=0.19) and also when *Salmonella* isolates and *Klebsiella pneumoniae* were compared (P=0.11). Significant difference was however observed when *Escherichia coli* and *Klebsiella pneumoniae* were compared (p=0.04).

#### **4.8 Antimicrobial susceptibility and ESBL test results**

Antimicrobial susceptibility test results indicated that all the forty two (42) isolates tested were susceptible to ceftriaxone, cefotaxime and cefuroxime. The *Salmonella Typhi* isolates were all susceptible to amoxicillin/clavulanic acid and gentamycin. High, but variable proportions of the isolates were susceptible to gentamycin (81.0%), ciprofloxacin (88.1%) and amoxicillin/clavulanic acid (73.8%). None of the 42 isolates was susceptible to ampicillin and tetracycline. Varied level of resistance of the isolates to the antimicrobial agents was also observed against chloramphenicol (97.6%) and cotrimoxazole (85.7%). None of the 42 bacterial isolates produced ESBL. The details of these results are presented in table 4.4.

Table 4.4: Antimicrobial susceptibility test results of the isolates obtained at Half Assini.

| Antibiotics                 | Bacterial isolates/number sensitive  |                               |                                |                            |                   |
|-----------------------------|--------------------------------------|-------------------------------|--------------------------------|----------------------------|-------------------|
|                             | <i>Salmonella Choleraesuis</i> (n=5) | <i>Salmonella Typhi</i> (n=4) | <i>Escherichia coli</i> (n=27) | <i>K. pneumoniae</i> (n=6) | Total susceptible |
| Ceftriaxone                 | 5 (100%)                             | 4 (100%)                      | 27(100%)                       | 6 (100%)                   | 42 (100%)         |
| Cefotaxime                  | 5 (100%)                             | 4 (100%)                      | 27 (100%)                      | 6 (100%)                   | 42 (100%)         |
| Cefuroxime                  | 5 (100%)                             | 4 (100%)                      | 27 (100%)                      | 6 (100%)                   | 42 (100%)         |
| Ciprofloxacin               | 5 (100%)                             | 4 (100%)                      | 24 (88.9%)                     | 5 (83.3%)                  | 37 (88.1%)        |
| Gentamycin                  | 4 (80%)                              | 4 (100%)                      | 21 (77.8%)                     | 5 (83.3%)                  | 34 (81.0%)        |
| Amoxicillin/clavulanic acid | 5 (100%)                             | 4 (100%)                      | 17 (63.0%)                     | 5 (83.33%)                 | 31 (73.8%)        |
| Cotrimoxazole               | 0 (0%)                               | 1 (25.0%)                     | 2 (7.4%)                       | 3 (50.0%)                  | 6 (14.3%)         |
| Chloramphenicol             | 0 (0%)                               | 1 (25.0%)                     | 0(0.0%)                        | 0 (0.0%)                   | 1 (2.4%)          |
| Ampicillin                  | 0 (0.0%)                             | 0 (0.0%)                      | 0 (0.0%)                       | 0 (0.0%)                   | 0(0.0%)           |
| Tetracycline                | 0 (0.0%)                             | 0 (0.0%)                      | 0 (0.0%)                       | 0 (0.0%)                   | 0(0.0%)           |

**4.9 Characterization of Salmonella isolates by Pulsed –Field Gel Electrophoresis** The Salmonella isolates were characterised by Pulsed –Field Gel Electrophoresis (PFGE) by detecting variations or otherwise among them at the level of their Deoxyribonucleic Acid (DNA) as shown in Figure 4.1. All the *Salmonella Choleraesuis* showed similar pattern of DNA separation. The *Salmonella Typhi* isolates also showed similar separation of bands when subjected to electrical field.




Figure 4.1 PFGE images of *Salmonella Choleraesuis* and *Salmonella Typhi*.

A, E and J were the controls used [*Salmonella Braenderup* (H9812)].

B, C, D, F and G were the test organisms (*Salmonella Choleraesuis*).

H, I, K and L were the test organisms (*Salmonella Typhi*).

## CHAPTER FIVE

### DISCUSSION

#### 5.1 The bacterial isolates obtained in relation to the age of patients

There were 9 *Salmonella* isolates obtained from subjects who took part in this study. They comprised of 5 *Salmonella Choleraesuis* forming 55.6% and 4 *Salmonella Typhi* forming 44.6% of the *Salmonellae*. The isolation of only *Salmonella Choleraesuis* did not agree with result of a study in Brazil where *Salmonella Typhimurium* and *Salmonella Enteritidis* were the predominant serovars isolated (Yamatogi et al., 2015). This is probably due to the ecological factors which affect serovar distribution (Agbaje et al., 2011). These ecological factors include the environmental cleanliness, availability of safe water source and the presence of animal reservoir for transmission.

The *Salmonella Choleraesuis* isolates were mostly obtained from subjects at the age extremes. In this study, 40% of the non-typhoidal *Salmonellae* were isolated from patients under 3 years. Another 40 % ( 2/5) were also isolated in subjects above 70 years. This is in conformity with a study in Kenya where children less than 3 years were at a higher risk of nontyphoidal *Salmonella* infection (Brent et al., 2006). It is similar to a study carried out in Malawi where 85% of the non-typhoidal *Salmonellae* were obtained from children less than 3 years (Gordon, 2008). This could be attributed to the transmission of the *Salmonella* bacteria being through faecal-oral route, as children play in the environment, they pick the pathogen from the contaminated ground into their mouth (Rivera-Chávez & Bäumler, 2015) .

Old age has been reported as a risk factor for acquisition of non-typhoidal *Salmonella* in African population (Morpeth et al., 2009). This is so because the elderly have waned (reduced) immunity. Matheson and his co researchers also ascertained this in their study where they stated that adults above 50 years were at a risk of infection (Matheson et al., 2010). This is consistent with the results obtained in this study where 40% of the nontyphoidal *Salmonella* were isolated in subjects above 70 years.

The age of the patients infected with other Gram negative organisms was evenly distributed, that is the organisms show no age preference. This finding supports a report in Kumasi, Ghana where *Klebsiella pneumoniae* and *Escherichia coli* showed no significant preference for age (Feglo, 2011). This is so because the isolates were opportunistic pathogens and they can only infect and cause diseases when the opportunity is created. This current report was not in agreement with the findings by Preethishrees and others where both *Escherichia coli* and *Klebsiella species* were mostly isolated in patients between sixty one years to seventy years (Preethishree et al., 2016). This could probably be due to differences in the age of the patients recruited into the study.

## **5.2 The bacterial isolates obtained in relation to the gender of patients**

More females were infected with the bacterial isolates (66.7%) as compared to the male patients (33.3%). This may be due to the fact that women mostly perform domestic duties like washing and bathing of the children as well as farming activities, hence they are more prone to the infection as compared to their male counterparts who mostly engage in sea fishing. In the present study, female patients constituted majority of the patients hence the higher possibility of isolating bacteria from them.

There was no significant difference in the gender of the patients infected with the bacterial isolates. This may be due to the fact the lactose-fermenting isolates are opportunistic pathogens and can equally infect both genders if the opportunity is created.

### **5.3 The bacterial isolates obtained in relation to the sample from which they were isolated**

All the *Salmonella Choleraesuis* were isolated from stool sample, with none from the blood and urine. The *Salmonella Choleraesuis* is largely adapted to pigs (Agbaje et al., 2011). Isolation of these bacteria in man may mean faecal contamination of the environment by pigs or consumption of undercooked pork (Agbaje et al., 2011).

In this current study, the predominant isolates were *Escherichia coli* and were obtained from urine samples. A similar pattern was also seen in South Africa where *Escherichia coli* bacteria were responsible for causing 75% to 95% of urinary tract infections in women (Van Schoor, 2016). The high level of isolation of *Escherichia coli* from urine sample was because unlike *Klebsiella pneumoniae* and *Salmonella* isolates, *Escherichia coli* are able to adapt to bladder environment, causing urinary tract infections (S. L. Chen et al., 2013).

### **5.4 Antimicrobial susceptibility of the bacterial isolates**

All the 42 isolates were susceptible to ceftriaxone, cefotaxime and cefuroxime. In Half Assini Government Hospital where the facility for culture and sensitivity is available, clinicians most of the time rely on the laboratory result before prescribing antibiotics. This could have accounted for high level of susceptibility of the bacterial isolates to these antibiotics. This agrees with a study in Tamale, Ghana where high susceptibility was reported for ceftriaxone (Adzitey et al., 2015).

All the 9 *Salmonella* isolates were susceptible to ciprofloxacin. This is in conformity with what was reported in Akwatia, Ghana where there were high level of susceptibility of the

Salmonella isolates to ciprofloxacin (Dakorah, 2014). This could be as a result of high cost of ciprofloxacin making it inaccessible to most of the patients in Half Assini. It however did not support a study by Imanishi and Chai in United States of America where susceptibility was 68% for *Salmonella Typhimurium* and 76% for *Salmonella Heidelberg* (Imanishi & Chai, 2013).

All the isolates tested against ampicillin and tetracyclines were resistant in this study. These antibiotics have been abused over the years. They are not expensive and can easily be bought over the counter.


Bacterial isolates were resistant to chloramphenicol (97.1%) and cotrimoxazole (85.7%). This is in conformity with a study by Odetoyin and his researchers in Nigeria where high level of resistance by *Escherichia coli* was reported against ampicillin and tetracycline (Odetoyin et al., 2016). These antibiotics have been used indiscriminately in humans and poultry. They were put into poultry feeds and used as growth promoters, accounting for high level of resistance recorded. (Odetoyin et al., 2016).

Susceptibility or resistance to antimicrobial agent can be influenced by many factors among which can be abuse of antimicrobial agents and inaccurate dosage by over-the counter medicine sellers and patients not following complete course of treatment. These have led to different susceptibility patterns around the globe.

**5.5 The bacterial isolates and extended spectrum beta lactamase production** All the 42 isolates were non ESBL producers. This is consistent with a study conducted by in La Cote d' Ivoire in 2012 where no Salmonella isolates produced ESBL (Boni-Cissé et al., 2012). On the contrary, a study in Korle Bu Teaching Hospital reported high ESBL production (47%) among 300 enterobacteria (Obeng-Nkrumah *et al.*, 2013). The antibiotic usage in Korle Bu will be higher than in Half Assini. The teaching hospital is situated in

the Accra, Ghana where most patients can easily afford expensive antibiotics, even without prescriptions. On the contrary, Half Assini is rural, so many isolates might not have encountered many of the antibiotics in circulation.

In Half Assini Hospital where this present study was carried out, strict adherence to safe and hygienic practices, including hand safety is the norm. This is to prevent the case where health care givers become vehicle for transmission. The hospital has the facility for culture and sensitivity, guiding the clinicians on the choice of antibiotics; hence the case where clinicians prescribed antibiotics without laboratory investigations is not part of the hospital culture.



## CHAPTER 6

### 6.0 Conclusion and recommendation

#### 6.1 Conclusion

Samples from 384 patients were cultured. A total of 42 isolates were obtained. Seven (16.7%) of the isolates were obtained from blood and 8(19.0%) were also obtained from stool. The total number of bacteria isolated from urine was 27 being 64.3% of the total isolates. The prevalence of *Salmonella* isolates was 2.3% and that of *Klebsiella pneumoniae* was 1.6%. *Escherichia coli* prevalence was at 7.0%.

This study revealed that non-typhoidal *Salmonella* (*Salmonella Choleraesuis*) affect more females than males and they mostly affect females at their age extremes. The *Salmonella Choleraesuis* isolated were not blood invasive.

All the bacterial isolated were susceptible to ceftriaxone, cefotaxime and cefuroxime. All the *Salmonella* isolates were also susceptible to ciprofloxacin. High but varied proportions of the isolates were also susceptible to gentamycin (88.10%) and amoxicillin/clavulanic acid (80.95%). All the isolates were resistant to tetracycline and ampicillin. Most of the isolates were also resistant to chloramphenicol (97.62%) and cotrimoxazole (85.72%).

None of the isolates produced ESBL.

From PFGE result, all the 5 *Salmonella Choleraesuis* exhibited similar separation of DNA. The 4 *Salmonella Typhi* also exhibited related based on DNA band size and separation.

### 6.3 Recommendations

- i. Ceftriaxone, cefotaxime and cefuroxime are recommended for treatment of infections caused by *Salmonella Choleraesuis*, *Salmonella Typhi*, *Escherichia coli* and *Klebsiella pneumoniae*.
- ii. More health education should be done on the spread and prevention of Salmonella and other Gram negative bacteria as well as on the judicious use of antibiotics. iii.

Equipment for culture and sensitivity should be provided to district hospitals in the country. This will help reduce the case where clinicians prescribe antibiotics without testing.



## REFERENCES

- Abdullahi, B., Olonitola, O., Jatau, E., & Usman, A. (2012). Serological characterization and antimicrobial susceptibility patterns of clinical isolates of Salmonella from patients attending general hospital, Funtua, Nigeria. *Bayero Journal of Pure and Applied Sciences*, 5(1), 72-77.
- Acheson, D., & Hohmann, E. L. (2001). Nontyphoidal salmonellosis. *Clinical Infectious Diseases*, 32(2), 263-269.
- Achouri, S., Wright, J. A., Evans, L., Macleod, C., Fraser, G., Cicuta, P., & Bryant, C. E. (2015). The frequency and duration of Salmonella–macrophage adhesion events determines infection efficiency. *Philosophical Transactions of the Royal Society of London B: Biological Sciences*, 370(1661), 20140033.
- Adzitey, F., Nafisah, S., & Haruna, A. (2015). Antibiotic Susceptibility of Escherichia coli Isolated from some Drinking Water Sources in Tamale Metropolis of Ghana. *Current Research in Bacteriology*, 8(2), 34.
- Afroza, S. (2003). Typhoid fever in children-An Update. *Review Article. Journal of Bangladesh College of Physicians and Surgeons*, 21, 141-148.
- Agbaje, M., Begum, R., Oyekunle, M., Ojo, O., & Adenubi, O. (2011). Evolution of Salmonella nomenclature: a critical note. *Folia microbiologica*, 56(6), 497-503.
- Ansaruzzaman, M., Kibriya, A., Rahman, A., Neogi, P., Faruque, A., Rowe, B., & Albert, M. J. (1995). Detection of provisional serovars of Shigella dysenteriae and designation as S. dysenteriae serotypes 14 and 15. *Journal of clinical microbiology*, 33(5), 1423-1425.
- Ao, T. T., Feasey, N. A., Gordon, M. A., Keddy, K. H., Angulo, F. J., & Crump, J. A. (2015). Global burden of invasive nontyphoidal Salmonella disease, 2010. *Emerging infectious diseases*, 21(6), 941.
- Asmar, B. I., & Abdel-Haq, N. (2016). Nontyphoidal Salmonella infection in children: relation to bacteremia, age, and infecting serotype. *Infectious Diseases*, 48(2), 147-151.
- Baylis, C., Uyttendaele, M., Joosten, H., & Davies, A. (2011). The Enterobacteriaceae and their significance to the food industry. *The Enterobacteriaceae and their significance to the food industry*, 7-12.
- Behravesh, C. B., Brinson, D., Hopkins, B. A., & Gomez, T. M. (2014). Backyard poultry flocks and salmonellosis: a recurring, yet preventable public health challenge. *Clinical Infectious Diseases*, 58(10), 1432-1438.
- Boni-Cissé, C., Meité, S., Faye-Ketté, H., Houedanou, C., Timité-Konan, M., Kalpi, C., Bakayoko, S., Nguesseng, N. and Soumahoro, K. (2012). Serotypes and antibiograms of Salmonella isolated at the University Teaching Hospital of Yopougon, Abidjan, Cote d'Ivoire from 2005 to 2009. *Journals of Microbiology and Antimicrobials*, 4, 40-44.
- Boore, A. L., Hoekstra, R. M., Iwamoto, M., Fields, P. I., Bishop, R. D., & Swerdlow, D. L. (2015). Salmonella enterica Infections in the United States and Assessment of Coefficients of Variation: A Novel Approach to Identify Epidemiologic Characteristics of Individual Serotypes, 1996–2011. *PLoS One*, 10(12), e0145416.

- Brent, A. J., Oundo, J. O., Mwangi, I., Ochola, L., Lowe, B., & Berkley, J. A. (2006). Salmonella bacteremia in Kenyan children. *The Pediatric infectious disease journal*, 25(3), 230-236.
- Chen, H.-M., Wang, Y., Su, L.-H., & Chiu, C.-H. (2013). Nontyphoid salmonella infection: microbiology, clinical features, and antimicrobial therapy. *Pediatrics & Neonatology*, 54(3), 147-152.
- Chen, S. L., Wu, M., Henderson, J. P., Hooton, T. M., Hibbing, M. E., Hultgren, S. J., & Gordon, J. I. (2013). Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. *Science translational medicine*, 5(184), 184ra160-184ra160.
- Crum-Cianflone, N. F. (2008). Salmonellosis and the gastrointestinal tract: more than just peanut butter. *Current gastroenterology reports*, 10(4), 424-431.
- Crump, J. A., Sjölund-Karlsson, M., Gordon, M. A., & Parry, C. M. (2015). Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. *Clinical microbiology reviews*, 28(4), 901-937.
- Dakorah, M. P. (2014). *Prevalence of salmonella Infections in Patients Attending St. Dominic Hospital,(Akwatia)-Eastern Region*. A thesis submitted to the Department of Clinical Microbiology, Kwame Nkrumah University of Science and Technology, Kumasi, in fulfillment of the award of Master of Philosophy in Clinical Microbiology, 2014
- Dhanao, A., & Fatt, Q. K. (2009). Non-typhoidal Salmonella bacteraemia: epidemiology, clinical characteristics and its' association with severe immunosuppression. *Annals of clinical microbiology and antimicrobials*, 8(1), 15.
- Eguale, T., Gebreyes, W. A., Asrat, D., Alemayehu, H., Gunn, J. S., & Engidawork, E. (2015). Non-typhoidal Salmonella serotypes, antimicrobial resistance and coinfection with parasites among patients with diarrhea and other gastrointestinal complaints in Addis Ababa, Ethiopia. *BMC infectious diseases*, 15(1), 1-2.
- Ellingson, K., Haas, J. P., Aiello, A. E., Kusek, L., Maragakis, L. L., Olmsted, R. N., Perencevich, E., Polgreen, P.M., Schweizer, M.L. and Trexler, P. (2014). Strategies to prevent healthcare-associated infections through hand hygiene. *Infection Control & Hospital Epidemiology*, 35(S2), S155-S178.
- Feasey, N. A., Archer, B. N., Heyderman, R. S., Sooka, A., Dennis, B., Gordon, M. A., & Keddy, K. H. (2010). Typhoid fever and invasive nontyphoid salmonellosis, Malawi and South Africa. *Emerging infectious diseases*, 16(9), 1448.
- Feglo, P. (2011). *Molecular Epidemiology of Extended Spectrum B-LactamaseProducing Enterobacteriaceae at the Komfo Anokye Teaching Hospital*. A thesis submitted to the School of Medical Sciences, Department of Clinical Microbiology, Kwame Nkrumah University of Science and Technology Kumasi in partial fulfilment of the requirements for the award of the degree of Doctor of Philosophy in Clinical Microbiology, 2011.
- Figueira, R., & Holden, D. W. (2012). Functions of the Salmonella pathogenicity island 2 (SPI-2) type III secretion system effectors. *Microbiology*, 158(5), 1147-1161.
- Gendrel, D., Kombila, M., Beaudoin-Leblevec, G. v., & Richard-Lenoble, D. (1994). Nontyphoidal salmonellal septicemia in Gabonese children infected with *Schistosoma intercalatum*. *Clinical Infectious Diseases*, 18(1), 103-105.

- Ghafourian, S., Sekawi, Z., Neela, V., Khosravi, A., Rahbar, M., & Sadeghifard, N. (2012). Incidence of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in patients with urinary tract infection. *Sao Paulo Medical Journal*, *130*(1), 37-43.
- Gordon, M. A. (2008). Salmonella infections in immunocompromised adults. *Journal of Infection*, *56*(6), 413-422.
- Gordon, M. A., Graham, S. M., Walsh, A. L., Wilson, L., Phiri, A., Molyneux, E., . . . Molyneux, M. E. (2008). Epidemics of invasive *Salmonella enterica* serovar enteritidis and *S. enterica* Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. *Clinical Infectious Diseases*, *46*(7), 963-969.
- Hachem, R. Y., Chemaly, R. F., Ahmar, C. A., Jiang, Y., Boktour, M. R., Rjaili, G. A., Bodey G.P. and Raad, I. I. (2007). Colistin is effective in treatment of infections caused by multidrug-resistant *Pseudomonas aeruginosa* in cancer patients. *Antimicrobial agents and chemotherapy*, *51*(6), 1905-1911.
- Hijazi, S., Fawzi, M., Ali, F., & El Galil, K. A. (2016). Prevalence and characterization of extended-spectrum beta-lactamases producing Enterobacteriaceae in healthy children and associated risk factors. *Annals of clinical microbiology and antimicrobials*, *15*(1), 1-3.
- Imanishi, M., & Chai, S. J. (2013). Salmonellosis (Nontyphoidal). *CDC Health Information for International Travel 2014: The Yellow Book*, 285.
- Ito, H., Kido, N., Arakawa, Y., Ohta, M., Sugiyama, T., & Kato, N. (1991). Possible mechanisms underlying the slow lactose fermentation phenotype in *Shigella* spp. *Applied and environmental microbiology*, *57*(10), 2912-2917.
- Jones, T. F., Ingram, L. A., Cieslak, P. R., Vugia, D. J., Tobin-D'Angelo, M., Hurd, S., Medus, C., Cronquist, A. and Angulo, F. J. (2008). Salmonellosis outcomes differ substantially by serotype. *Journal of Infectious Diseases*, *198*(1), 109-114.
- Kalonji, L. M., Post, A., Phoba, M.-F., Falay, D., Ngbonda, D., Muyembe, J.-J., Bertrand, S., Ceysens P.J., Mattheus W. and Verhaegen, J. (2015). Invasive Salmonella Infections at Multiple Surveillance Sites in the Democratic Republic of the Congo, 2011–2014. *Clinical Infectious Diseases*, *61*(suppl 4), S346-S353.
- Kariuki, S., Revathi, G., Kariuki, N., Kiiru, J., Mwituria, J., & Hart, C. A. (2006). Characterisation of community acquired non-typhoidal *Salmonella* from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. *BMC microbiology*, *6*(1), 101-104.
- Kiratisin, P. (2008). Bacteraemia due to non-typhoidal *Salmonella* in Thailand: clinical and microbiological analysis. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, *102*(4), 384-388.
- Kwambana-Adams, B., Darboe, S., Nabwera, H., Foster-Nyarko, E., Ikumapayi, U. N., Secka, O., Betts M., Bradbury R., Wegmuller R. and Lawal, B. (2015). Salmonella Infections in The Gambia, 2005–2015. *Clinical Infectious Diseases*, *61*(suppl 4), S354-S362.
- Labi, A., Yawson, A., Ganyaglo, G., & Newman, M. (2015). Prevalence and associated risk factors of asymptomatic bacteriuria in ante-natal clients in a large teaching hospital in Ghana. *Ghana medical journal*, *49*(3), 154-158.
- Lamberti, L. M., Bourgeois, A. L., Walker, C. L. F., Black, R. E., & Sack, D. (2014). Estimating diarrheal illness and deaths attributable to *Shigellae* and

- enterotoxigenic *Escherichia coli* among older children, adolescents, and adults in South Asia and Africa. *PLoS Negl Trop Dis*, 8(2), e2705.
- Laxminarayan, R., Matsoso, P., Pant, S., Brower, C., Røttingen, J.-A., Klugman, K., & Davies, S. (2016). Access to effective antimicrobials: a worldwide challenge. *The Lancet*, 387(10014), 168-175.
- Lübbert, C., Straube, L., Stein, C., Makarewicz, O., Schubert, S., Mössner, J. and Rodloff, A. C. (2015). Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. *International Journal of Medical Microbiology*, 305(1), 148-156.
- Lukac, M., Pedersen, K., & Prukner-Radovic, E. (2015). Prevalence of *Salmonella* in captive reptiles from Croatia. *Journal of Zoo and Wildlife Medicine*, 46(2), 234-240.
- Luvsansharav, U.-O., Hirai, I., Nakata, A., Imura, K., Yamauchi, K., Niki, M., and Yamamoto, Y. (2012). Prevalence of and risk factors associated with faecal carriage of CTX-M  $\beta$ -lactamase-producing Enterobacteriaceae in rural Thai communities. *Journal of Antimicrobial Chemotherapy*, 67(7), 1769-1774.
- Lwanga, S. K., & Lemeshow, S. (1991). *Sample size determination in health studies: a practical manual*: World Health Organization.
- Mabey, D., Brown, A., & Greenwood, B. (1987). *Plasmodium falciparum* malaria and *Salmonella* infections in Gambian children. *The Journal of infectious diseases*, 1319-1321.
- MacLennan, C. A., Gondwe, E. N., Msefula, C. L., Kingsley, R. A., Thomson, N. R., White, S. A., and Dougan, G. (2008). The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of *Salmonella* in African children. *Journal of Clinical Investigation*, 118(4), 1553-1562.
- Mahmood, K., Izhar, M., Nakhshab Choudhry, G. M., & Rashid, N. (2012). Emergence of extended-spectrum  $\beta$ -lactamase producing *Salmonella typhi* in Pakistan. *African Journal of Microbiology Research*, 6(4), 793-797.
- Majowicz, S. E., Musto, J., Scallan, E., Angulo, F. J., Kirk, M., O'Brien, S. J., Jones, T.F., Fazil, A. and Hoekstra, R. M. (2010). The global burden of nontyphoidal *Salmonella* gastroenteritis. *Clinical Infectious Diseases*, 50(6), 882-889.
- Martins, F. S., Elian, S. D., Vieira, A. T., Tiago, F. C., Martins, A. K., Silva, F. C., and Pimenta, P. F. (2011). Oral treatment with *Saccharomyces cerevisiae* strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. *International Journal of Medical Microbiology*, 301(4), 359-364.
- Matheson, N., Kingsley, R. A., Sturgess, K., Aliyu, S. H., Wain, J., Dougan, G., & Cooke, F. J. (2010). Ten years experience of *Salmonella* infections in Cambridge, UK. *Journal of Infection*, 60(1), 21-25.
- Milledge, J., Calis, J. C. J., Graham, S. M., Phiri, A., Wilson, L. K., Soko, D., and Molyneux, E. M. (2005). Aetiology of neonatal sepsis in Blantyre, Malawi: 1996-2001. *Annals of Tropical Paediatrics: International Child Health*, 25(2), 101-110.
- Morpeth, S. C., Ramadhani, H. O., & Crump, J. A. (2009). Invasive non-typhi *Salmonella* disease in Africa. *Clinical Infectious Diseases*, 49(4), 606-611.

- Mossoro-Kpinde, C. D., Manirakiza, A., Mbecko, J.-R., Misatou, P., Le Faou, A., & Frank, T. (2015). Antimicrobial Resistance of Enteric Salmonella in Bangui, Central African Republic. *Journal of Tropical Medicine*, 2015.
- Mounier, J., Vasselon, T., Hellio, R., Lesourd, M., & Sansonetti, P. (1992). Shigella flexneri enters human colonic Caco-2 epithelial cells through the basolateral pole. *Infection and immunity*, 60(1), 237-248.
- Mulisa, G., Selassie, L., Jarso, G., Shiferew, T., & Zewdu, A. (2015). Prevalence of Extended Spectrum Beta-lactamase Producing Enterobacteriaceae: A Cross Sectional Study at Adama Hospital, Adama, Ethiopia. *Journal of Emerging Infectious Disease*, 1(102), 2-7.
- Naing, L., Winn, T., & Rusli, B. (2006). Practical issues in calculating the sample size for prevalence studies. *Archives of orofacial Sciences*, 1(1), 9-14.
- Nesa, M., Khan, M., & Alam, M. (2012). Isolation, identification and characterization of salmonella serovars from diarrhoeic stool samples of human. *Bangladesh Journal of Veterinary Medicine*, 9(1), 85-93.
- Obeng-Nkrumah, N., Twum-Danso, K., Krogfelt, K. A., & Newman, M. J. (2013). High levels of extended-spectrum beta-lactamases in a major teaching hospital in Ghana: the need for regular monitoring and evaluation of antibiotic resistance. *The American journal of tropical medicine and hygiene*, 89(5), 960-964.
- Odetoyin, B. W., Hofmann, J., Aboderin, A. O., & Okeke, I. N. (2016). Diarrhoeagenic Escherichia coli in mother-child Pairs in Ile-Ife, South Western Nigeria. *BMC infectious diseases*, 16(1), 1.
- Okonko, I., Ijandipe, L., Ilusanya, O., Donbraye-Emmanuel, O., Ejembi, J., Udeze, A., and Nkang, A. (2009). Incidence of urinary tract infection (UTI) among pregnant women in Ibadan, South-Western Nigeria. *African Journal of Biotechnology*, 8(23), 5-11.
- Onanuga, A., & Selekere, T. L. (2016). Virulence and antimicrobial resistance of common urinary bacteria from asymptomatic students of Niger Delta University, Amassoma, Bayelsa State, Nigeria. *Journal of Pharmacy And Bioallied Sciences*, 8(1), 29.
- Oneko, M., Kariuki, S., Muturi-Kioi, V., Otieno, K., Otieno, V. O., Williamson, J. M. and Mahon, B. E. (2015). Emergence of Community-Acquired, MultidrugResistant Invasive Nontyphoidal Salmonella Disease in Rural Western Kenya, 2009–2013. *Clinical Infectious Diseases*, 61(suppl 4), S310-S316.
- Paterson, D. L. (2006). Resistance in gram-negative bacteria: Enterobacteriaceae. *The American journal of medicine*, 119(6), S20-S28.
- Paterson, D. L., & Bonomo, R. A. (2005). Extended-spectrum  $\beta$ -lactamases: a clinical update. *Clinical microbiology reviews*, 18(4), 657-686.
- Pitzer, V. E., Feasey, N. A., Msefula, C., Mallewa, J., Kennedy, N., Dube, Q., Denis B., Gordon, M.A. andHeyderman, R. S. (2015). Mathematical Modeling to Assess the Drivers of the Recent Emergence of Typhoid Fever in Blantyre, Malawi. *Clinical Infectious Diseases*, 61(suppl 4), S251-S258.
- Preethishree, P., Rai, R., Kumar, K. V., Pai, K. A., & Bhat, U. P. (2016). Uropathogens and their antibiotic susceptibility pattern at a tertiary care teaching hospital in Coastal Karnataka, India. *International Journal of Current Microbiology and Applied Sciences* 5(1), 23-31.

- Quinn, T. C. (2015). 52. Sexually transmitted enteric infections. *Clinical Infectious Disease*, 352.
- Raffatellu, M., Chessa, D., Wilson, R. P., Tükel, Ç., Akçelik, M., & Bäumler, A. J. (2006). Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis. *Infection and immunity*, 74(1), 19-27.
- Raja, S., Khan, A., & Cheema, H. (2015). Tracing transmission of *Salmonella enterica* subsp. *enterica* in tomato fruits. *International Journal of Agriculture and Biology*, 17(6), 1255-1259.
- Ram, P., Crump, J., Gupta, S., Miller, M., & Mintz, E. (2008). Part II. Analysis of data gaps pertaining to *Shigella* infections in low and medium human development index countries, 1984–2005. *Epidemiology and infection*, 136(05), 577-603.
- Ribot, E. M., Fitzgerald, C., Kubota, K., Swaminathan, B., & Barrett, T. J. (2001). Rapid pulsed-field gel electrophoresis protocol for subtyping of *Campylobacter jejuni*. *Journal of clinical microbiology*, 39(5), 1889-1894.
- Rivera-Chávez, F., & Bäumler, A. J. (2015). The Pyromaniac Inside You: *Salmonella* Metabolism in the Host Gut. *Annual review of microbiology*, 69, 31-48.
- Rupp, M. E., & Fey, P. D. (2003). Extended spectrum  $\beta$ -lactamase (ESBL)-producing Enterobacteriaceae. *Drugs*, 63(4), 353-365.
- Ryan, K. J., & Ray, C. G. (2004). *Medical microbiology*: McGraw Hill.
- Saana, S. B. M., Adu, F., Gbedema, S., & Duredoh, F. (2014). Antibiotic susceptibility patterns of *Salmonella Typhi* among patients in three hospitals in Kumasi, Ghana. *International Journal of Pharmaceutical Sciences and Research*, 5(3), 855.
- Schlundt, J., Toyofuku, H., Jansen, J., & Herbst, S. (2004). Emerging food-borne zoonoses. *Revue Scientifique et Technique-Office International des Epizooties*, 23(2), 513-534.
- Smith, D., Diack, H., & Hugh, T. (2005). Pennington: Food Poisoning. *Policy and Politics: Corned Beef and Typhoid in Britain in the 1960s*. Boydell Press, UK., ISBN, 1-84383.
- Sorrells, K. M., Speck, M. L., & Warren, J. A. (1970). Pathogenicity of *Salmonella gallinarum* after metabolic injury by freezing. *Applied microbiology*, 19(1), 3943.
- Srinivasan, A., Wolfenden, L. L., Song, X., Mackie, K., Hartsell, T. L., Jones, H. D., Diette, G.B., Orens, J.B., Yung, R.C. and Ross, T. L. (2003). An outbreak of *Pseudomonas aeruginosa* infections associated with flexible bronchoscopes. *New England Journal of Medicine*, 348(3), 221-227.
- Suzuki, T., & Sasakawa, C. (2001). Molecular basis of the intracellular spreading of *Shigella*. *Infection and immunity*, 69(10), 5959-5966.
- Tandé, D., Jallot, N., Bougoudogo, F., Montagnon, T., Gouriou, S., & Sizun, J. (2009). Extended-Spectrum  $\beta$ -Lactamase-Producing Enterobacteriaceae in a Malian Orphanage. *Emerging infectious diseases*, 15(3), 472.
- Tennant, S. M., Diallo, S., Levy, H., Livio, S., Sow, S. O., Tapia, M., Fields, P.I., Mikoleit, M., Tamboura, B. and Kotloff, K. L. (2010). Identification by PCR of non-typhoidal *Salmonella enterica* serovars associated with invasive infections among febrile patients in Mali. *PLoS Negl Trop Dis*, 4(3), e621.
- Tennant, S. M., Zhang, Y., Galen, J. E., Geddes, C. D., & Levine, M. M. (2011). Ultrafast and sensitive detection of non-typhoidal *Salmonella* using

- microwaveaccelerated metal-enhanced fluorescence (MAMEF). *PLoS One*, 6(4), e18700.
- Thompson, F., Gevers, D., Thompson, C., Dawyndt, P., Naser, S., Hoste, B., Munn, C. and Swings, J. (2005). Phylogeny and molecular identification of vibrios on the basis of multilocus sequence analysis. *Applied and environmental microbiology*, 71(9), 5107-5115.
- Upadhyaya, I., Upadhyay, A., Kollanoor-Johny, A., Mooyottu, S., Baskaran, S. A., Yin, H.B., Schreiber, D.T., Khan, M.I., Darre M.J. and Curtis, P. A. (2015). In-Feed Supplementation of trans-Cinnamaldehyde Reduces Layer-Chicken Egg-Borne Transmission of *Salmonella enterica* Serovar Enteritidis. *Applied and environmental microbiology*, 81(9), 2985-2994.
- Van Doren, J. M., Neil, K. P., Parish, M., Gieraltowski, L., Gould, L. H., & Gombas, K. L. (2013). Foodborne illness outbreaks from microbial contaminants in spices, 1973–2010. *Food microbiology*, 36(2), 456-464.
- Van Schoor, J. (2016). Urinary tract infections in women. *South African Family Practice*, 58(1), 6-10.
- Velge, P., Wiedemann, A., Rosselin, M., Abed, N., Boumart, Z., Chaussé, A.-M., Grepinet, O., Namdari, F., Roche, S. and Rossignol, A. (2012). Multiplicity of *Salmonella* entry mechanisms, a new paradigm for *Salmonella* pathogenesis. *Microbiologyopen*, 1(3), 243-258.
- Vieira, A., Jensen, A. R., Pires, S. M., Karlsmose, S., Wegener, H. C., & Wong, D. L. F. (2009). *WHO Global Foodborne Infections Network Country Databank a resource to link human and non-human sources of Salmonella*. Paper presented at the 12th International Symposium on Veterinary Epidemiology and Economics, Durban, South Africa.
- Wilson, A., Livermore, D., Otter, J., Warren, R., Jenks, P., Enoch, D., . . . McNulty, C. (2016). Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party. *The Journal of hospital infection*, 92, S1-S44.
- Yamatogi, R. S., Oliveira, H. C., Camargo, C. H., Fernandes, S. A., Hernandez, R. T., Pinto, J. P., Rall, V.L. and Araújo, J. P. (2015). Clonal relatedness and resistance patterns of *Salmonella* Corvallis from poultry carcasses in a Brazilian slaughterhouse. *The Journal of Infection in Developing Countries*, 9(10), 11611165.

# KNUST

## APPENDICES

### Appendix 3.7.1A: Composition and preparation of culture media

#### Composition of brain heart infusion broth (LAB M LIMITED, UNITED KINGDOM)

|   |            |
|---|------------|
| i. Brain-Heart Infusion solids(Porcine)           | 17.5g      |
| ii. Tryptose      10.0g    iii. Glucose      2.0g |            |
| iv. Sodium chloride                               | 5.0g    v. |
| Disodium Hydrogen Phosphate                       | 2.5g       |
| vi. Distilled water                               | 1L         |

#### Preparation of brain heart infusion broth

37g of the powder was dissolved in 1L of distilled water. The suspension was soaked for 10 minutes, swirled to mix and warmed gently to dissolve the powder completely. The mixture was dispensed into culture bottles and sterilise by autoclaving at 121°C at 15 pounds pressure for 15 minutes.

**Composition of Selenite F Broth (Rapid Labs, United Kingdom)**

|                       |      |                     |       |
|-----------------------|------|---------------------|-------|
| i. Peptone            | 5.0g | ii. Lactose         | 4.0g  |
| iii. Sodium phosphate |      |                     | 10.0g |
|                       |      | iv. Sodium Selenite | 4g    |
| v. Distilled water    |      |                     | 1L    |

**Preparation of Selenite F broth**

4g of Sodium Selenite and 19g of powder was added to 1L of distilled water.

Mixture was warmed until the powder dissolved.

Mixture was distributed into bottles and sterilised for 10 minutes in boiling water.

**Composition of blood agar base (ACCUMIX, INDIA)**

|                 |  |       |      |
|-----------------|--|-------|------|
| i. Beef Heart   |  | 500g  | ii.  |
| Sodium chloride |  | 5.0g  | iii. |
| Tryptose        |  | 10.0g |      |
| iv. Agar        |  | 15.0g |      |

**Preparation of blood agar base**

40.0g of the powder was suspended in 1L of distilled water. Suspension was thoroughly mixed.

Mixture was brought to boil with frequent agitation to dissolve the powder completely.

Mixture was sterilised by autoclaving for 15 minutes at 15 pounds pressure at 121°C.

Blood agar was prepared from this as follows:

The base was cooled to 45°C and 5% v/v sterile blood was added. The blood and the base were thoroughly mixed well. Plates were poured into sterilised petri plates.

**Composition of MacConkey agar (ACCUMIX, INDIA)**

|                          |       |
|--------------------------|-------|
| i. Peptone               | 20.0g |
| ii. Lactose              | 10.0g |
| iii. Neutral red         | 0.04g |
| iv. Sodium taurochlorate | 20.0  |
| v. Agar                  | 20.0g |

**Preparation of MacConkey agar**

55.0g of the powder was suspended in 1000ml distilled water and thoroughly mixed. Suspension was brought to boil with frequent agitation to dissolve the powder completely

Mixture was sterilised by autoclaving at 121°C at 15 pounds pressure for 15 minutes.

**Composition of Salmonella-Shigella agar (RAPID LABS, UNITED KINGDOM)**

|   |        |      |
|---|--------|------|
| i. Peptones                                   | 4.0g   | ii.  |
| Beef extract                                  | 4.0g   | iii. |
| Lactose                                       | 10.0g  |      |
| iv. Brilliant green                           | 0.33mg |      |
| v. Bile salts                                 | 8.0g   | vi.  |
| Na <sub>2</sub> S <sub>2</sub> O <sub>3</sub> | 8.0g   |      |
| vii. Sodium citrate                           | 8.0g   |      |
| viii. Ferric citrate                          | 1.0g   | ix.  |
| Neutral red                                   | 0.025g |      |
| x. Agar                                       | 11.50g |      |

- |                     |    |
|---------------------|----|
| xi. Distilled water | 1L |
|---------------------|----|

### Preparation of Salmonella Shigella agar

54.5g of the powder was added to 1L of distilled water.

The suspension was swirl to mix and brought to boil.

The mixture was allowed to cool to 47°C, mixed well and the plates were poured.

### Composition of Cystine Lactose Electrolyte Deficient (CLED) agar

- |                       |        |      |
|-----------------------|--------|------|
| i. Tryptone           | 4.0g   | ii.  |
| Peptone               | 4.0g   | iii. |
| Lactose               | 10.0g  |      |
| iv. Beef extract      | 3.0g   |      |
| v. L- cystine         | 0.128g |      |
| vi. Bromothymol blue  | 0.02g  |      |
| vii. Agar             | 15.0g  |      |
| viii. Distilled water | 1L     |      |

### Preparation of cystine lactose electrolyte deficient (CLED) agar

36.15g of the powder was suspended in 1L of distilled water. The suspension was thoroughly mixed and brought to boil with frequent agitation to dissolve the powder completely. Sterilisation was done by autoclaving at 121°C for 15 minutes at 15 pounds pressure.

### Composition of urea agar base (BIOMARK, INDIA)

- |                                   |      |
|-----------------------------------|------|
| i. Peptic digest of animal tissue | 1.0g |
| ii. Dextrose                      | 1.0g |

|       |                         |        |      |
|-------|-------------------------|--------|------|
| iii.  | Sodium chloride         | 5.0g   | iv.  |
|       | Disodium phosphate      | 1.20g  | v.   |
|       | Monopotassium phosphate | 0.80g  |      |
| vi.   | Phenol red              | 0.012g | vii. |
|       | Agar                    | 15.0g  |      |
| viii. | Distilled water         | 1L     |      |

### Preparation of urea agar base

24g of the powder was suspended in 950 ml of distilled water.

Suspension was boiled to dissolve the medium completely.

Sterilisation was done by autoclaving at 10 pounds pressure at 115°C for 20 minutes.

Mixture was cooled to 50°C and 50ml of 40% urea solution was added and mixed thoroughly.

Mixture was dispensed into sterilised tubes and allowed to set in a slant position.

### Preparation of urea solution

40g of urea powder was dissolved into 100ml of sterile distilled water and gently mixed.

### Composition of nutrient agar (ACCUMIX, INDIA)

|      |                 |       |
|------|-----------------|-------|
| i.   | Peptone         | 5.0g  |
| ii.  | Sodium chloride | 5.0g  |
| iii. | Beef extract    | 1.5g  |
| iv.  | Yeast extract   | 1.5g  |
| v.   | Agar            | 15.0g |

### Preparation of nutrient agar

28g of the powder was suspended in 1L of distilled water.

The suspension was thoroughly mixed.

Suspension was boiled with frequent agitation to dissolve the powder completely. Sterilisation was done by autoclaving the mixture at a pressure of 15 pounds pressure for 15 minutes at 121°C.

Mixture was allowed to cool to 45°C and the plates were poured into sterilised petri plates.

### Composition of Mueller Hinton agar

|                            |       |          |
|----------------------------|-------|----------|
| i. Casein acid hydrolysate | 17.5g | ii.      |
| Beef heart infusion        | 2.0g  |          |
| iii. Starch                | 1.5g  | iv. Agar |
|                            |       | 17.0g    |

### Preparation of Mueller Hinton agar

38g of the powder was suspended in 1L of distilled water. The suspension was thoroughly mixed.

Suspension was boiled with frequent agitation to dissolve the powder completely. Sterilisation was done by autoclaving the mixture at a pressure of 15 pounds pressure for 15 minutes at 121°C. Mixture was allowed to cool to 45°C and the plates were poured into sterilised petri plates.

### Composition of triple sugar iron agar (BIOMARK, INDIA)

|                                   |       |             |
|-----------------------------------|-------|-------------|
| i. Peptic digest of animal tissue | 10.0g | ii.         |
| Casein enzymic hydrolysate        | 10.0g |             |
| iii. Yeast extract                | 3.0g  | iv.         |
| Beef extract                      | 3.0g  |             |
| v. Lactose                        | 10.0g | vi. Sucrose |
|                                   |       | 10.0g       |
| vii. Dextrose                     | 1.0g  |             |

|       |                     |           |
|-------|---------------------|-----------|
| viii. | Sodium chloride     | 5.0g ix.  |
|       | Ferrous sulphate    | 0.20g x.  |
|       | Sodium thiosulphate | 0.30g xi. |
|       | Phenol red          | 0.024g    |
| xii.  | Agar                | 12.0g     |
| xiii. | Distilled water     | 1L        |

#### **Preparation of triple sugar iron agar**

65g of the powder was suspended into 1L of distilled water.

Suspension was brought to boil, mixed well and distributed into tubes.

Sterilisation was done by autoclaving the mixture at a pressure of 15 pounds pressure for 15 minutes at 121°C.

The medium was allowed to set in a slope form.

#### **Composition of motility- indole -ornithine medium (BD, USA)**

|                               |       |
|-------------------------------|-------|
| Pancreatic Digest of Casein   | 9.5g  |
| Pancreatic Digest of Gelatin  | 10.0g |
| Yeast Extract                 | 3.0g  |
| Dextrose                      | 1.5g  |
| L-Ornithine Monohydrochloride | 5.0g  |
| Bromocresol Purple            | 0.02g |
| Agar                          | 2.0g  |
| Distilled water               | 1L    |

#### **Preparation of motility- indole- ornithine medium**

31g of the powder was suspended in 1L of distilled water.

The suspension was mixed well.

The suspension was brought to boil with frequent agitation for complete dissolution of the powder

The mixture was dispensed in screw-capped tubes and sterilised in an autoclave at 121°C for 15 minutes at 15 pounds pressure. The prepared medium was stored at 4°C.

#### **Composition of Simmon's citrate agar (BIOMARK, INDIA)**

|                                   |           |
|-----------------------------------|-----------|
| i. Magnesium sulphate             | 0.20g     |
| ii. Ammonium dihydrogen phosphate | 1.0g iii. |
| Dipotassium phosphate             | 1.0g iv.  |
| Sodium citrate                    | 2.0g v.   |
| Sodium chloride                   | 5.0g vi.  |
| Bromothymol blue                  | 0.08g     |
| vii. Agar                         | 15.0g     |
| viii. Distilled water             | 1L        |

#### **Preparation of Simmon's citrate agar**

24.28g of the powder was suspended in 1L of distilled water. Medium was boiled for complete dissolution of the powder. Medium was sterilised at 1bar pressure for 15 minutes at 121°C at 15 pounds pressure.

#### **Composition of peptone water (ACCUMIX, Belgium)**

|                     |           |
|---------------------|-----------|
| i. Peptone          | 10.0g     |
| ii. Sodium chloride | 5.0g iii. |
| Distilled water     | 1L        |

#### **Preparation of peptone water**

15g of the powder was suspended in 1L of distilled water. The suspension was mixed thoroughly

The suspension was warmed slightly with frequent agitation to dissolve the powder completely.

The mixture was dispensed into tubes and sterilised at 1bar pressure for 15 minutes at 121°C 15 pounds pressure.

#### **Appendix 3.7.1B: Dispensing of the prepared media**

- i. Sterile petri dishes were laid out on a level surface.
- ii. Media were mixed by rotation of the flask and bottle gently.
- iii. The necks of the flasks and bottles were flame sterilised.
- iv. 15ml of the medium was poured into the petri dish and allowed to set.
- v. Prepared media were stored in a refrigerator at a temperature of 4°C.

#### **APPENDIX 3.10 IDENTIFICATION OF ISOLATES USING ANALYTICAL PROFILE INDEX**

API ID 32E is a standardised, miniaturized microtube system consisting of 32 biochemical tests for identification for Enterobacteriaceae and other non- fastidious Gram negative rods. The 32 microtubes contain dehydrated substrates.

The 32 biochemical tests were:

- ODC- Ornithine decarboxylase
- ADH- Arginine dihydrolase
- LDC- Lysine decarboxylase
- URE- Urease
- LARL- L-Arabitol (Acidification)
- GAT- Galacturonate (Acidification)
- 5KG- 5- Ketoglutarate (Acidification)
- LIP- Lipase

- RP- Phenol red(Acidification)
- $\beta$ GLU-  $\beta$ -Glucosidase
- MAN- Mannitol (Acidification)
- MAL- Maltose (Acidification)
- ADO- Adonitol (Acidification)
- PLE- Palatinose (Acidification)
- $\beta$ GUR-  $\beta$ -Glucuronidase (Acidification)
- MNT- Malonate
- IND- Indole production
- $\beta$ NAG- N-acetyl- $\beta$ -glucosaminidase
- $\beta$ GAL-  $\beta$ -Galactosidase
- GLU- Glucose(Acidification)
- SAC- Saccharose (Acidification)
- LARA- L-Arabinose (Acidification)
- DARL- D-Arabitol (Acidification)
- $\alpha$ GLU-  $\alpha$ -Glucosidase
- $\alpha$ GAL-  $\alpha$ -Galactosidase
- TRE- Trehalose (Acidification)
- RHA- Rhamnose (Acidification)
- INO- Inositol (Acidification)
- CEL- Cellobiose (Acidification)
- SOR- Sorbitol (Acidification)
- $\alpha$ MAL-  $\alpha$ -Maltosidase
- AspA- L-Aspartic acid arylamidase

In performing the test, a single well isolated colony was emulsified in an ampoule containing 3ml sterile normal saline until the turbidity was equivalent to

0.5McFarland. Each of the 32 microtubes was filled with 55µl of the suspension with automatic pipette.

The following tests were covered with by overlaying 2 drops of mineral oil so as to obtain anaerobic conditions: ODC, ADH, LDC, URE, LARL, GAT and 5KG. They were then incubated at 37°C for 24 hours aerobically.

After the 24 hour incubation period, were read using the mini API instrument. One drop of James reagent was added to the 'IND' well (to reveal the indole reaction) before it was read. Positive test results were scored as a seven digit number (profile). The identity of the bacteria is then derived from the database with relevant identification software.

#### **Appendix 3.12.1 Principle of urease test**

The basis of this test is to test the ability of the organism to produce urease which splits urea into ammonium and carbon dioxide. The alkaline product is detected by phenol red which is pink in alkaline medium and yellow in acid medium, thus a positive reaction will appear as pink-red.

#### **Appendix 3.12.2. Principle of the motility, indole, ornithine test.**

Motile organisms cause turbidity in the medium as they diffuse from the stab line. Organisms initially ferment dextrose forming acidic environment which cause the bromo cresol purple which is a pH indicator to change from purple to yellow. If the organisms possess ornithine decarboxylase, the ornithine will be decarboxylated to putrescine which increases the PH making it alkaline, resulting to a colour change from the yellow to purple. Indole production is detected by the ability of the organisms to break down tryptophan to indole by the action of tryptophanase.

### **Appendix 3.12.3 Principle of the triple sugar iron agar test**

Triple sugar iron agar contains dextrose, sucrose and lactose with phenol red and ferrous ammonium sulphide as indicators. If the organism ferments only dextrose, an acidic environment is created in both the slant and the butt, creating a yellow colour in the butt. On the slant however, aerobic fermentation or respiration takes place and not enough acid is produced to lower the Ph, so the colour remains red.

If sucrose or lactose is fermented, enough acid is produced resulting in the phenol red indicator turning yellow in both the slant and the butt. Gas production may result from the fermentation and can be detected as bubbles trapped in the agar or splitting of pushing the agar upwards.

Hydrogen sulphide production is detected by the ferrous ammonium sulphate incorporated into the medium. This reacts with Hydrogen sulphide forming ferrous sulphide; an insoluble black precipitate.

### **Appendix 3.12.4 Principle of the citrate test**

The principle of this test is to test the ability of the organism to utilise citrate as the only carbon source for metabolism. If this occurs, an alkaline environment is created which changes the initial green colour to blue.

### **Appendix 3.13.0 Principle of the serological test**

The principle of this test is the clumping or agglutination of the suspected Salmonella isolates with their specific antibodies in the antiserum. Because the antibodies were known, the antigen can be detected since antibodies react with their homologous antigens.

### **Appendix 3.14 Preparation of 0.5 McFarland**

- i. 1% v/v solution of sulphuric acid was prepared by adding 1 ml of the concentrated acid to 99ml of water.
- ii. 1%w/v of barium chloride was prepared by dissolving 0.5g of barium chloride in 50ml distilled water.
- iii. 99.4ml of sulphuric acid solution was added to 0.6ml of barium chloride solution and mixed.

### **Appendix 3.15.0 Principle of Extended Spectrum Beta Lactamase detection**

ESBL are beta lactamases that confers resistance to penicillins, first generation, second generation and third generation cephalosporins by hydrolysing these antibiotics. In the presence of clavulanic acid however, the beta lactamase effect is inhibited.

### **3.16.0 Principle behind Pulsed-Field Gel Electrophoresis**

Pulsed-Field Gel Electrophoresis allows for the separation of extremely large DNA fragments when subject to an electric field that constantly changes direction. This is done by digesting genomic DNA using restriction enzyme, resulting to several DNA fragments. These fragments are then subjected to an electric field, producing a DNA fingerprint pattern.

### **3.16.1 Procedure for Pulsed-Field Gel Electrophoresis**

- i. The sample for this procedure was a fresh overnight culture.
- ii. 800µl of cell suspension buffer(appendix 3.16.1 R1) was pipetted into 5ml tubes (1 tube for each bacterial strain, 1 tube for Salmonella Braenderup [H9812] control strain and 1 tube to serve as a blank for turbidity measurement).
- iii. A sterile cotton wool swab was used to pick some bacterial colonies from the agar plate and suspended into the suspension buffer.

- iv. Turbidity of the cell suspension was measured using Dade Behring Microscan turbidity meter to read 0.70. The tubes were kept on an ice after the reading to prevent bacterial multiplication thereby increasing the turbidity.
- v. 200  $\mu$ l of the cell suspension was transferred into a 1.5ml tube. 20  $\mu$ l of 20mg/ml proteinase K (appendix 3.16.1 R2). The tube was gently tapped with fingers to mix the suspension. The tube was incubated at 37°C for 5 minutes using a thermomixer.
- vi. 280  $\mu$ l of a 1% SeaKem Gold agarose: 1%SDS mixture (appendix 3.16.1 R3) (held at 55°C). The molten agarose was gently mixed with the bacterial sample. 300  $\mu$ l of the mixture was transferred into a BIORAD plug mould. 10 minutes allowed for the agarose block to solidify.
- vii. The plug mould was opened and the agarose plug was transferred to a 50ml screw-cap tube using a small spatula, which was cleaned with 70% alcohol between each step.
- viii. 5ml of lysis buffer (appendix 3.16.1 R4) was added and incubated at 55°C for 120 minutes with gentle shaking using a shaking water bath at a speed of 70rpm.
- ix. The blue screw cap of the 50ml tube was replaced with a green strainer. The lysis buffer was poured out. 15ml of preheated deionised water at 50°C was added to wash the block for 15 minutes at 50°C in a shaking water bath at a speed of 70rpm. The water was poured out and this wash step was repeated.
- x. The water was poured out and 15ml of preheated (50°C) TE buffer (appendix 3.16.1 R5) was added. Washing was done for 15 minutes at 50°C in a shaking water bath at a speed of 70rpm. The wash step was repeated another 5 times.
- xi. 100  $\mu$ l of 1x restriction enzyme buffer (appendix 3.16.1 R6) in a 1.5ml tube.

- xii. The agarose plug was placed onto a glass slide and 2mm thick slice of the plug was cut using scalpel blade. The blade was clean with 70% alcohol between each cut.
- xiii. The agarose slice was placed into the 1x restriction enzyme buffer and incubated for 15 minutes at 37°C.
- xiv. The 1x buffer was pipetted out and 150 µl of fresh 1x restriction enzyme buffer containing 50 units of restriction enzyme (appendix 3.16.1 R7) was added. Incubation was done for 4 hours at 37°C.
- xv. The buffer/enzyme mix was pipetted out and 200 µl of 0.5x TBE (appendix 3.16.1 R8) was added. Incubation was done for 10 minutes at room temperature.
- xvi. The agarose slice was removed from the tube and attached to a comb. The comb was placed within a BIORAD agarose gel casting unit.
- xvii. A 150ml solution of 1% SeaKem Gold agarose (appendix 3.16.1 R9) was prepared, allowed to cool to 50°C, and poured into the agarose gel casting unit. 25 minutes was allowed for the gel to solidify.
- xviii. Electrophoresis running buffer (0.5xTBE) (appendix 3.16.1 R8) was prepared and the electrophoresis chamber of a BIORAD CHEF-DR was filled with the buffer. The cooling unit was set to a run temperature of 14°C and the running buffer was allowed to chill for 30 minutes before the electrophoresis was started. The temperature was checked with a thermometer to ensure that it was really at 14°C.
- xix. The gel was removed from the casting unit and placed onto its resting position within the electrophoresis chamber of the BIORAD CHEF-DR III electrophoresis system.

xx. The electrophoresis run parameters was set as follows:

- a. Initial switch time                      2.2 seconds
- b. Final switch time                        63.8 seconds
- c. Included angle                            120<sup>0</sup>
- d. Voltage                                      6 volts
- e. Run time                                     19 hours

xxi Electrophoresis run was started.

xxii After the run, the agarose gel was removed from the electrophoresis chamber and placed into a plastic container. 250ml of Ethidium bromide staining solution (appendix 3.16.1 R8) was added and incubated at room temperature for 30 minutes with gentle shaking.

xxiii The staining solution was removed from the container, and 400ml of deionised water was added and destained with gentle shaking at room temperature for 30 minutes. The water was changed after 15 minutes of distaining.

xxiv An image of the DNA fingerprint was captured using BIORAB gel documentation system

**Appendix 3.16.1 Constituents of reagents used for Pulsed-Field Gel Electrophoresis**

**Appendix 3.16.1 R1 :Cell suspension buffer (100mM Tris: 100mM EDTA, pH 8)**

10ml of 1M Tris, pH 8

20ml of 0.5M EDTA, pH 8

70ml deionised water

**Appendix 3.16.1 R2: Proteinase-K (20mg/ml)**

20mg proteinase-K

1ml TE buffer (3.20.1 R5)

**Appendix 3.16.1 R3: 1% SeaKem Gold agarose:1% SDS mixture**

0.25g SeaKem Gold agarose

22.5ml TE buffer (3.20.1 R5)

The suspension was dissolved by boiling in a microwave oven and allowed to cool to 50°C. 2.5 ml of 10% SDS (3.20.1 R11) was added and mixed thoroughly at 55°C.

**Appendix 3.16.1 R4: Lysis buffer**

0.5M EDTA, pH 8

1% N-lauroylsarcosine sodium salt (sarcosyl) [freshly added]

0.1 mg/ml proteinase-K (freshly added)

**Appendix 3.16.1 R5: Tris-EDTA(TE) buffer (10Mm Tris: 1Mm EDTA, pH 8)**

10ml of 1 M Tris, pH 8

2ml of 0.5M EDTA, pH 8

988ml of deionised water

**Appendix 3.16.1 R6: 1x restriction enzyme buffer**

Deionised water            90µl

10x buffer                    10µl

**Appendix 3.16.1 R7: 1x restriction enzyme buffer with restriction enzyme**

10x buffer                    15 µl

Enzyme (10U/ µl)            5 µl

Deionised water            130 µl

**Appendix 3.16.1 R8: 0.5x TBE buffer**

50ml of 10x TBE (3.20.1 R12)

950ml deionised water

**Appendix 3.16.1 R9: 1% SeaKem Gold agarose**

1.5g SeaKem Gold agarose

150ml of 0.5x TBE buffer (3.20.1 R8)

The suspension was dissolved in a microwave oven until the powder dissolved.

**Appendix 3.16.1 R10: Ethidium bromide staining solution**

250ml of 0.5x TBE (3.20.1 R8)

25 $\mu$ l of 10mg/ml Ethidium bromide

**Appendix 3.16.1 R11: 10% SDS**

10g Sodium dodecyl sulphate

100ml deionised water

**Appendix 3.16.1 R12: 10x TBE buffer**

108g Tris

55g Boric acid

7.5g EDTA powder

1000ml deionised water.

